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ATP                        adenosine triphosphate 
ADMET                       absorption,distribution,metabolism, excretion, toxicology 
CPMG   Carr-Purcell-Meiboom-Gill 
CRINEPT   cross-correlated relaxation enhanced polarisation 
CSP                            chemical shift perturbation 
DTT    dithiothreitol 
EDTA                          ethylenedimaminetetraaceticacid 
EPR                            electron paramagnetic resonance 
FBDD                         fragment based drug discovery 
GTP                          guanosine triphosphate 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSQC   heteronuclear single quantum coherence 
Hsp90   heat shock protein 90 
HTS   high throughput screening 
ILOE   inter-ligand overhauser effect 
IPTG   isopropyl β-D-1-thiogalactopyranoside 
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NMR   nuclear magnetic resonance 
NOESY                       nuclear overhauser effect spectroscopy 
PDB   protein data bank 
PRE    paramagnetic relaxation enhancement  
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RF   radio frequency 
RMSD            root mean square deviation 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
STD   saturation transfer difference 
TCEP    tris(2-carboxyethyl)phosphine 
TINS   target immobilized NMR screening 
TOCSY  total correlation spectroscopy 
Tris-HCl  trisaminomethane hydrochloride 



























































































Drug Discovery  
 
 
Discovery of new medicines has transitioned from serendipity to rationality 
over a period of time. A drug may be referred to as a substance that is either used in 
diagnosis, prevention or treatment of a disease and which carries out a physiological 
effect when ingested or otherwise introduced into the body. A drug carries out its 
action by binding to a therapeutic target.1 The pharmaceutical industry today invests 
between 10-20% of annual sales revenue in research and development, far greater 
as compared to other research-based sectors. The discovery of a drug molecule 
takes about 10 years and these timelines have led to a rise in the financial 
expenditure, estimated to be more than $500 million. These higher costs are 
associated with a significant risk, since many drug candidates fail to reach the clinic. 
Newer strategies are needed at an early stage of the drug discovery process to 
reduce the risk of failure and successfully identify potential drug candidates. Two 
main broad types of screening strategies are typically employed to find optimal drug 
candidates at a preclinical stage - phenotypic screening and target-based screening.  
Phenotypic v/s Target based Screens 
Phenotypic screening looks at the effects, or phenotypes (a set of observable 
characteristics of a disease), induced by the compounds in cells, tissues or whole 
organisms whereas target based screens measures the effect of compounds on a 
target protein using in vitro assays. Phenotypic screening leads to the identification of 
a small molecule that either modifies or alters disease phenotype by acting on an 
unknown target or by acting simultaneously on one or more targets. However, the 
challenge with phenotypic screening is that the subsequent determination of a 
relevant target or targets that interact with the candidate molecule has proven slow 
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The strength of target based screening is that the small molecule screening 
strategies can be applied against a known target (mostly in high-throughput formats). 
One can also apply molecular knowledge to investigate specific mechanisms such as 
if a binding of a drug results in an inhibition or activation of the target protein. Recent 
advances in molecular biology and chemical genomics have led to the identification 
of novel drug targets that are implicated in a number of diseases. As a result, 
phenotypic screens are now largely replaced by target based screens. The initial 
stage of target-based drug discovery programs consists of many sequential and 
iterative steps as illustrated in Figure 1.,Most pharmaceutical companies carry out 
multiple target-based screens in a drug discovery pipeline to achieve desired 
success in the drug development. 2,3
 
 
Figure 1. Outline of initial stages involved in a target based drug development. 
A. Target Identification/Validation 
One of the important steps in developing a new drug is the identification of a 




whose activity in the cell is associated with the onset or progression of a particular 
disease. A ‘ligandable’ target is one which is accessible to the putative drug 
molecule, be that a small molecule or larger biologicals. The understanding of 
fundamental processes and cellular networks associated with the target protein and 
cellular changes caused upon activation/inhibition of the target has been the
underlying approach to identify suitable targets for drug intervention. Validation of 
new drug targets is the process of physiologically, pathologically and 
pharmacologically evaluating the effects of a molecule on a protein target implicated 
in disease. Target validation can be performed at a molecular, cellular or the whole 
animal level.
    
B. Hit Discovery 
The main goal of the hit discovery stage is to identify small molecules or hits 
that harbor the potential to modulate the functional activity of the target protein. A hit 
is defined as a compound which exhibits desired activity in a small molecule screen 
against a target protein and whose activity can be confirmed upon retesting. Many 
potential screening approaches exist to discover hits. Most commonly used 
approaches are high-throughput screening (HTS), fragment and/or knowledge based 
screening.6,7  
 High-throughput screening (HTS) is the process of testing a large number (at 
least 10’s of thousand to a few million) of diverse ‘drug-like’ or ‘lead-like’ chemical 
structures (molecular weight between 250 - 600 Da) against disease targets to 
identify hits using binding, enzymatic or cellular assays. The emphasis in HTS is 
to select those compounds that bind to the target protein with a higher 
potency/binding affinity (typically <1 µM). Therefore, desired compounds need to 




hydrophobic and ionic interactions etc.) within the active site of a protein target.

 
However, HTS has potential limitations.  As HTS involves screening of large 
compound libraries, it becomes difficult to monitor the quality of compounds and 
manage the chemical diversity space of the HTS library (the chemical diversity space 
refers to the extent of variety in the atomic composition within a set of compounds). 
Inevitably, HTS screening decks may contain molecules that are not drug-like i.e. 
highly lipophilic and with poor aqueous solubility. As a result, hits that come from 
HTS consist of a large number of false positives (compounds that cause aggregation, 
are reactive molecules or redox active), false negatives and compounds with poor 
ADMET properties (absorption, distribution and metabolism). The inappropriate 
physico-chemical properties of compounds have led to high attrition rates during drug 
development (the attrition rate reflects the level of loss of new candidate drugs during 
the process from pre-clinical to clinical and through their clinical development).14-16 
The compounds with higher molecular weight and lipophilicity are the main drivers for 
attrition of molecules as they directly influence the ADMET properties. To reduce 
attrition rates, Lipinski and coworkers17 have proposed the famous “Rule of Five” 
(defined below).17 The rule provides the framework to develop drugs with better 
aqueous solubility and oral bioavailibility. The rule of 5 is the outcome from the 
analysis of physico-chemical properties of more than 2000 drugs and drug-like 
molecules in clinical trials. The rule concludes that a drug-like molecule is more likely 
to be membrane permeable and easily absorbed by the body if it matches the 
following criteria:  
• Molecular weight < 500 
• The compound's lipophilicity, expressed as a quantity known as ClogP (the 





• The number of groups in the molecule that can donate hydrogen atoms to 
hydrogen bonds (usually the sum of hydroxyl and amine groups in a drug 
molecule) < 5. 
The number of groups that can accept hydrogen atoms to form hydrogen bonds 
(estimated by the sum of oxygen and nitrogen atoms) < 10. 
Another potential limitation of HTS is that large compound libraries represent 
only a tiny fraction of chemical diversity space. It is estimated that there are about 
1060-200 possible drug-like compounds of HTS size (250-600 Da) while there are only 
approximately 109 possible molecules with 11 or fewer heavy atoms (C, N, O and F). 
This suggests that screening of 1,000 low molecular weight molecules (< 16 heavy 
atoms per compound) might sample total chemical space more effectively than 
screening 1,000,000 more typical, higher molecular weight HTS compounds (< 36 
heavy atoms per compound).  This poor sampling by HTS libraries has limited the 
confidence in finding of good starting points for subsequent optimization and 
development. There are various examples in several drug discovery projects where 
HTS has failed to generate meaningful potential hits. There is a constant need for 
alternative approaches so as to overcome the problems posed by HTS.18,19  
The fragment-based drug discovery (FBDD) approach is able to overcome the 
limitations posed by HTS and is an established method used within the 
pharmaceutical industry to develop drugs against a variety of diseases. FBDD 
involves the generation of very small molecular weight compounds (fragments) 
libraries that are screened at high concentrations. These fragments are then 
elaborated or grown into potent drug molecules. FBDD combines a stepwise 




biological targets to enable efficient hit to lead development (a lead molecule is a 
chemically optimized fragment hit with a better binding affinity to the protein target 
and is a more drug-like compound). FBDD is the primary approach in the work 
described in this thesis and will be described in detail in a later section.20  
Focused or knowledge-based screening involves selecting from the chemical 
library smaller subsets of molecules that are likely to have activity against the target 
protein. This selection of molecules is based on the prior knowledge of the target 
protein from literature and from the chemical classes that are likely to have activity at 
the drug target.5-7
C. Hit to Lead and Lead optimization 
Once a set of hits is obtained from compound screening, the next step is to 
narrow down which compounds are the best to progress. The initial refinement or 
also termed as “hit validation” is to generate dose-response curves in a suitable 
assay for each hit.4 A validated hit should ideally act reversibly with the drug target. It 
is important to initiate a drug discovery program with small simple molecules as the 
follow-up medicinal chemistry efforts tend to improve the potency at the expense of 
an increase in the molecular weight of a compound.8,9 The goal of the lead 
optimization phase is to maintain favorable ADMET properties while improving the 
deficiencies (chemical groups that are not critical for binding affinity) of the lead 
structure. The success of drug discovery programs largely depends on the 
successful development of lead series as these are pursued as potential drug 
candidates for subsequent studies. The availability of 3D structural information on the 
target protein-small molecule complexes is crucial at this stage of drug development 
as its inclusion allows developing lead compounds with better potency and favorable 




Fragment Based Drug Discovery 
Fragment based drug discovery (FBDD) is an established method. FBDD has 
significantly developed since last 10 years and a large number of pharmaceutical 
companies and academic groups are now actively involved. Despite being only few 
years in existence, FBDD has been able to deliver drug candidates in a timely 
fashion and there are approved drugs already on the market in addition to several 
clinical and pre-clinical drug candidates against a variety of protein targets. An 
extensive list of fragment-derived compounds has entered the clinical trials from 
various pharmaceutical companies. The current list contains 16 compounds in Phase 
I, 11 compounds in Phase II and 1 compound in Phase III clinical trials. One drug 
discovered from the fragment-screen has received FDA approval and is marketed 
under the name Zelboraf. The drug was discovered at Plexxikon Inc. and developed 
in partnership with Roche. The drug has shown dramatic clinical results and extends 
life of patients with a deadly form of skin cancer. More details on the clinical trial 
progression of fragment derived compounds is reviewed elsewhere.20,23  
FBDD starts with screening of small molecules, called “fragments” i.e. the 
minimal recognition motifs or molecular anchors.20 The origins for FBDD approach 
can be traced to a paper by Williams Jencks, in which it was proposed that weakly 
binding fragments can form high quality interactions (high binding energies per unit of 
molecular mass) with the target and later these fragments can be optimized to deliver 
highly potent lead-like molecules. Nakamura and Abeles applied FBDD approach 
and demonstrated that indeed it was possible to obtain potent HMG-CoA inhibitors 
when starting from weakly binding fragments.
/@=fragment based drug discovery 





1) Fragment library - in which a fragment collection is assembled  
2) Fragment screening- in which the fragment library is screenedon a purified 
protein target using an array of biophysical techniques that are able to detect 
weak, non-covalent binding to the target of interest and 
3) Fragment elaboration- during which validated fragments are developed in 
lead compounds guided by structure based drug design (SBDD) and 
biochemical data.  
 
             Fragment based approaches offer a number of attractive features: (i) a 
significantly larger proportion of chemical space can be sampled within a fragment 
library (usually ~103 fragments) than with the ~105−106 larger molecules typical for 
an HTS campaign. As a result, less number of compounds (about a few hundred up 
to a few thousand) are typically screened against the target protein (ii) fragments are 
small and have a greater probability of correctly matching the binding site of the 
target protein by forming high quality interactions. As a large number of atoms in a 
fragment hit are involved in direct protein-binding interaction, fragments are 
considered to be highly ligand efficient binders {Ligand efficiency (LE) is a 
measurement of the binding energy per atom of a ligand to its target protein and is a 
valuable metric to small molecules with different sizes} (iii) the chemical optimization 
of fragment hits (parameters such as potency, target selectivity, ADMET properties 
and LEs > 0.3) can be achieved when the protein-ligand binding interaction is 
structurally validated and (iv) fragments in a library are chosen such that they exhibit 
good aqueous solubility and should lead to fewer false positives arising from 






Although Lipinski’s rule of 5 provides useful guidelines to maximize an oral 
drug candidate success in the drug development, it may not be relevant to assess 
optimum properties of lead-like molecules. It has been reported that the libraries 
containing compounds with molecular weight 100-350 Da and clogP of 1-3 do result 
in hits which can be optimized into lead molecules with favorable drug-like properties. 
This suggests that smaller is better for efficient drug development. Fragment 
molecules in a library typically are compliant with the “Rule of Three” as proposed by 
Congreve and colleagues.24,25 Rule of 3 is used as the selection criteria and include 
physico-chemical characteristics such as molecular weight < 300 Da (~150-300 Da), 
fewer number of heavy atoms and a limited number of hydrogen bond donors 3 
and the number of hydrogen bond acceptor ≤ 3. Other criteria include the solubility, 
ClogP ≤ 3 and the number of rotatable bonds ≤ 3.23,24 
 
Fragment Screening 
Fragment hits are simple molecules and tend to bind weakly to the target 
protein. The typical binding affinities exhibited by fragment hits range between 0.01-
10 mM. Hence, to detect weak fragment hits, sensitive biophysical techniques are 
required. NMR (Nuclear Magnetic Resonance) and X-ray crystallography are 
commonly used techniques as they are able to detect hits within a range of binding 
affinities. The application of X-ray crystallography as a screening tool depends on 
number of factors such as availability of a large amount of protein, and access to 
synchrotron and time involved to screen for crystallization conditions.26,27 Other 
techniques like mass spectrometry, high concentration functional screening, 




may be easier to set-up for small molecule screening. 28-32 Significant importance 
should also be laid on choosing an appropriate biophysical technique for screening of 
fragments. For example, as noted by Jhoti and colleagues, only about 5% of the 
fragment population needs to interact with the protein to be detected as an NMR hit, 
whereas in X-ray crystallography experiments a fragment needs to have at least 70% 
occupancy of the binding site to be defined as a hit. Also, NMR can detect hits with 
solubilities lower than their potency for the target protein.33 To avoid the loss of any 
potential hits that come from a particular screening method and to aid in reliable 
identification of hits, often two or more techniques are employed early in the FBDD 
process.  
NMR as a screening tool in FBDD 
The popularity of NMR as a screening technique in the drug discovery process 
is increasing due to its sensitivity for the detection of the low affinity compounds. This 
section will mainly focus on NMR methods that are capable of detecting binding of 
small molecules to a protein target by screening of a compound library. NMR based 
screening can be implemented as ligand- or protein-detected methods.34 It is 
necessary to introduce some basic NMR concepts for a better understanding of the 
methods described in the later sections of this chapter.  
 
Basic Concepts for Ligand detected NMR Methods: 
Magnetization 
The nuclear magnetic resonance (NMR) spectroscopy experiment involves using 
energy in the form of electromagnetic radiation to transit the excess alpha nuclei (low 
energy ground state) into the beta state (high energy excited state). The energy in 




This energy is at a specific resonance frequency that depends on the strength of the 
applied external magnetic field and the magnetic properties of NMR active nuclei. 
The term ‘magnetization’ in NMR is simply the sum of all the individual nuclear 
magnetic moments possessed by respective nuclear spins in presence of the 
externally applied magnetic field. There is a very small energy difference between α 
(low energy ground state) and β (high energy excited state) energy states of a 
nuclear spin orientation in a magnetic field and this results in a very small excess 
population of nuclei in the ground state (Boltzmann distribution). For example, the 
population difference is only on the order of 1 in 105 for 1H spins in an 11.7T 
magnetic field. It is this small difference in the population that is responsible for an 
NMR signal.35.36  
Relaxation 
Relaxation in NMR is an important process and an understanding is required 
for proper measurement of the NMR spectra. Any spin system that is not in the 
equilibrium state will relax back to its Boltzmann distribution. This happens via two 
mechanisms called spin-lattice relaxation and spin-spin relaxation. The spin-lattice 
relaxation is a process by which the spins exchange energy with their surrounding 
medium. This can be pictured as a movement of the bulk magnetization of spins back 
into the direction of the external magnetic field. It is therefore also called longitudinal 
relaxation or T1-relaxation. The spin-spin relaxation is characterized by the loss of 
coherence among the spins. The spin-spin relaxation is also called transverse 
relaxation or T2-relaxation.35,36 
Chemical Exchange 
 As the binding of a small molecule ligand to the protein requires exchange 




rates affect the properties of the NMR spectra. The interconversion between the 
bound and free states is dependent on the Larmor frequency of the observed nucleus 
and field strength.If the exchange is slow i.e. in slow exchange as per NMR time 
scale (NMR time scale depends on the strength of the magnetic field and a particular 
experimental set-up), two separate resonances can be observed for the free and the 
bound state. In the intermediate exchange regime, target resonances that are 
sharp/intense at low ligand concentrations, broaden and sometimes disappear as the 
ligand concentration is increased. These broadened resonances reappear at high 
ligand concentrations and perhaps exhibit a small chemical shift. In “fast exchange” 
regime the spectral characteristics in the bound state are transferred to the free state 
of the ligand. The observed resonances are the population weighted averages of the 
signals of the free and the bound state and a single sharp signal can be detected.35-37  
Intrinsic NMR characteristics of a protein and a small molecule ligand 
The detection and characterization of protein-ligand interactions require 
different NMR techniques depending on the binding affinity, molecular weight and 
chemical exchange between free and bound state. A protein target exhibits 
characteristic properties such as slow diffusion, fast relaxation due to slower tumbling 
and fast spin-diffusion (spontaneous exchange of magnetization among nearby 
nuclear spins). A small molecule ligand possesses opposite properties such as fast 
diffusion, slower relaxation and negligible spin diffusion. In a protein-ligand complex, 
the properties of the bound ligand become similar to that of the protein. Acquisition of 
1D 1H NMR spectra of a ligand in the presence and absence of the protein may 
indicate binding via broadening of the resonance signal and/or loss of signal intensity 
of the ligand resonances. Most NMR assays exploit these differences in the 




Ligand detected NMR Methods 
NMR is a sensitive technique for probing the binding interaction of target 
protein with a small molecule or fragment using ligand-based NMR detection 
methods. Ligand-observed NMR methods are routinely used to generate hit matter (a 
primary set of compounds that bind the target protein). There are a number of ligand 
detected methods that are based on the acquisition of simple 1D 1H NMR 
experiments. There are two ways to detect ligand binding by ligand-detected NMR: 1) 
exploiting the difference in the tumbling of the ligand in the presence and absence of 
the protein targets (ligands that are bound to the protein will experience slower 
mobility and altered relaxation parameters). CPMG experiments and TINS (Target 
Immobilized NMR Screening) are good examples.38,39,40 In CPMG (Carr-Purcell-
Meiboom-Gill) experiment, a simple measure as the observation of a reduction in the 
intensity of the ligand proton resonance observed only in the presence of the protein 
target is considered as an indicator for ligand binding.38,39 TINS (Target immobilized 
NMR screening) is one of the technologies used extensively in the work described in 
this thesis and will be described in detail below.40 2) the transfer of 1H magnetization 
from protein to the bound ligand (only ligand molecules that bind to the protein will 
experience the magnetization transfer). STD and WaterLOGSY are routinely used 
techniques that exploit the magnetization transfer.41,42 There are a number of 
approaches that are developed to detect ligand binding such as diffusion editing, 19F 
fluorine screening and competition binding studies (provides information on the 
binding site) that can be implemented but will not be discussed here.26,43  
TINS 
TINS exploits the enhanced transverse relaxation rate (measure of how fast 




linewidth of an NMR signal) of the ligand caused by binding to a protein target 
immobilized on a solid support. The difference in the transverse relaxation rate 
between protein bound and free state of ligand is at least 2 orders of magnitude. Use 
of a reference protein along with the target protein eliminates those fragments that 
exhibit non-specific interactions to the protein surface. Target and reference proteins 
are immobilized on a commercially available resin. A flow-injection, dual-cell sample 
holder is placed into the magnet into which repeated cycles of mixtures of fragments 
about 3-6 fragments per mix are injected simultaneously on both the immobilized 
target and the reference cells. After injection, flow is stopped and NMR data are 
acquired followed by extensive washing prior to the next injection. In TINS, a small 
quantity of protein target is used and a fragment library of ~2000 compounds can be 
screened in less than 5 days. The change in the signal amplitude caused by the 
interaction of the fragment with either the target protein or the reference protein is 
termed as the TINS effect.12,40,44,45 TINS can also be set-up in competition mode 
allowing one to rapidly characterize the ligand binding site using a known competitor. 
TINS NMR screening has been successfully applied to diverse classes of protein 
targets including kinases, viral RdRP's (RNA dependent RNA polymerase), GTPases 
and also to challenging membrane proteins. The technique is sensitive, robust and 
efficient for the detection of weak binders. 
STD and WaterLOGSY 
The saturation transfer difference (STD) experiment is widely adopted for 
screening purposes and was developed originally by Mayer and Meyer.41 The STD 
experiment is the difference between two separate experiments. In a first experiment 
so called “on resonance”, the protein proton magnetization is saturated (saturation 




and as a result no NMR signal is observed) by a train of selective rf (radio frequency) 
pulses. The saturation is placed on the isolated resonances of the protein, usually 
around the methyl region (~0.0 to -1.0 ppm) such that these do not overlap with the 
ligand resonances. The selective saturation of e.g. the methyl 1H’s is then transferred 
to nearby protons within the protein via intramolecular 1H-1H cross relaxation 
pathways, referred to as spin diffusion. When a ligand binds to the protein, the 
saturation is transferred via intermolecular 1H-1H cross relaxation at the binding 
interface. These saturated ligand molecules upon dissociation from the target protein 
are exchanged back into solution where their saturated state persists. As more ligand 
molecules are exchanged on and off the protein, the population of the saturated 
ligand builds up in solution. In another experiment so called “off resonance”, the 
saturation is applied far away from protein resonances, e.g. at 100 ppm, such that no 
saturation of the protein is observed. The “off resonance” spectrum is used as a 
reference. The “on resonance” and “off resonance” experiments are acquired in an 
interleaved fashion and then subtracted. The resulting difference spectrum between 
the “on resonance” and “off resonance” experiments yields only those ligand 
resonances that experience saturation arising exclusively from the ligand binding to 
the target protein. STD experiments have several advantages: i) STD experiments 
can be carried out with less protein concentration (~1-5 µM) compared to other ligand 
detected NMR methods, (ii) compounds can be screened in mixtures (iii) ease of 
implementation and (iv) applicability to large molecular weight targets.43 Mayer and 
co-workers46 have also demonstrated that STD can be used for group epitope 
mapping in which only those specific protons of the ligand that are closer to the 
protein surface experience a higher degree of saturation. This type of information can 




There are potential pitfalls with STD technique that need to be considered 
before implementing to a protein-ligand system. The STD effect is limited by the 
exchange regime. To get maximum sensitivity of STD signal, ligand has to dissociate 
at a faster rate, this is caused by the difference in the relaxation rate of the ligand 
when free and when bound to the protein target. During STD experiment, one 
assumes that protein is 100% saturated. However, this may not be always true as the 
saturation is also lost to solvent protons and other saturated protein protons. Also, 
some protein targets are suboptimal for STD, in which another similar approach, 
WaterLOGSY (WaterLOGSY (Water-ligand Observed via Gradient SpectroscopY) 
may be more effective.41,43 In WaterLOGSY experiment, the saturation pulse is 
applied at the resonance frequency of the bulk water. The transfer of saturation is 
achieved from water to the protein target and subsequently from protein target to the 
ligand. This transfer relies on the presence of bound water molecules within ligand 
binding site of the protein.  It is to be noted that the ligand observed NMR techniques 
are dependent on the “fast exchange regime” between the ligand and the target 
protein. A ligand that is bound tightly is in “slow exchange” and is not suitable for 
detection by ligand observed NMR methods.37,43 
  
Fragment Elaboration and Structure Based Drug Design 
Typically, FBDD campaigns are combined with structure-based drug design 
(SBDD). SBDD has emerged as a new tool in medicinal chemistry. Identification of 
initial fragments from a direct binding assay is most useful if it is also supported by 
structural information such as the binding site of the fragment. The initial fragment 
hits can be considered as building blocks of a complex series of lead compounds. 




achieved by designing of small subset of compounds that make additional specific 
interactions within the binding site of the target protein. SBDD requires the three 
dimensional structure or closely related structure of a homolog or a NMR derived 
structure of the target protein, preferentially complexed with a ligand. The 3D 
structure of the protein-ligand complex reveals the binding mode and the 
conformation of a compound under investigation and indicates the essential 
molecular interactions determining its binding affinity. Small molecules could be 
modeled into a binding pocket of the drug target using various computational tools.37-
39,51 As noted by Hajduk and Greer, the inclusion of structural information derived 
from methods such as X-ray crystallography and NMR could dramatically influences 
the success of fragment based drug design.24 The ability to increase the potency of 
inhibitors nearly triples with the aid of structure-based design. The development of 
selective inhibitors for cyclin-dependent kinase-2 (CDK-2), Src-kinase,  matrix 
metalloproteinase 3  and Hsp90 are very good examples where SBDD have helped 
to achieve potent compounds.52-55 Fragment-based screening coupled with structure-
based drug design provides a powerful combination for maximizing the 
representation of chemical diversity space and generating novel, potent inhibitors for 
various protein targets.  
The FBDD approach has been highly successful and to date at least 25 drugs 
derived from FBDD and have entered the clinical trials.One drug discovered from the 
fragment-screen has received FDA approval and is marketed under the name 
Zelboraf. The drug was discovered at Plexxikon Inc. and developed in partnership 
with Roche. The drug has shown dramatic clinical results and extends life of patients 
with a deadly form of skin cancer.20,23,47 A particularly impressive example was the 




partner proteins. The initial work was published in 2005 showing how very potent 
inhibitors (< 100 nM) were discovered starting from the identification and subsequent 
NMR structure determination of two weak fragments with 300 M and 4 mM affinities, 
respectively.49 The example shows how FBDD has the potential to deliver drugs even 
for protein-protein interaction targets. A more recent application was the identification 
of small molecule binding to a novel site on the protein survivin.50 The structure of an 
NMR-derived protein–ligand complex was determined for one of the fragments 
obtained from a fragment screen and subsequent optimization allowed the 
identification of compounds with affinities of < 100 nM. These compounds are 
suitable probes for understanding the role of the novel binding site in cancer 
biology.48,50 About 13 different institutions reported the development of more than 50 
potent compounds (IC50 < 100 nM; IC50 is the concentration of an inhibitor required 
for 50% inhibition of an enzyme) against different protein targets starting from weakly 
binding fragments.22 There are many successful examples of application of FBDD to 
obtain high affinity leads which are reviewed elsewhere.20,21 
 
X-ray Crystallography as a Structural Tool 
To date, X-ray crystallography has been the main driver for structure 
determination purposes. Soaking of small molecules into protein crystals is a 
successful approach to obtain high resolution 3D structural information of the protein-
small molecule complexes. There have been many examples where the use of X-ray 
crystallography has aided the successful discovery of nanomolar potent inhibitors 
against protein targets such as p38 MAP kinase, β-secretase, urokinase, Src-kinase, 
cyclin dependent kinase-2 (CDK2) to name a few.56 The X-ray structure of the 




delivers the relevant structural information for initiating lead optimization via 
medicinal and/or combinatorial chemistry attempts. However, in practice, it is not 
always possible to obtain protein-small molecule costructures because of different 
experimental causes. The set-up for X-ray based structure determination is not trivial 
and is both resource and time intensive. Common problem is faced with the 
interpretation of electron density maps determined from X-ray diffraction experiments 
(An electron density map is a three-dimensional description of the electron density in 
a crystal structure, determined from X-ray diffraction experiments). This can be 
ambiguous and even at resolution of 1.5 to 2.5 Å, there are uncertainties in the 
placement of amino acid residues like asparagine, glutamine and histidine because 
of their internal pseudo-symmetry. In the case of asparagine and glutamine, the side-
chain N and O atoms will have similar electron densities, and in the case of histidine, 
the N and C atoms of the imidazole ring will usually be indistinguishable (and 
consequently the side-chains of these residues can typically be built in two 
orientations). Errors in the placement of ligands (including fragments) in 
macromolecular crystal structures can also arise from several causes. Non-
covalently bound compounds may exhibit greater thermal motion or conformational 
disorder than the surrounding protein, leading to poor electron density.57-60 Artifacts 
may be generated by the crystallization process itself. Potential blocking of the target 
site by crystal contacts (interchain or intermolecular contacts that occur solely as a 
result of crystallization) can result in false-negatives upon soaking ligands. Similarly, 
residues surrounding the site of interest could be held in an inappropriate 
conformation for ligand binding, or could be blocked by other ligands.61 Additionally, 
crystals that are grown at extremes of pH may not yield ligand-binding modes 




chains. Also, not all protein targets can be crystallized and may not be amenable for 
crystallography set-up. NMR spectroscopy has proven to be an alternative choice 
and in some cases an appropriate technique to obtain 3D structural information on 
the protein-ligand complexes.  
 
NMR Spectroscopy as a Structural Tool 
NMR plays an important role in the process of identification of fragment hits 
and developing them into high affinity and selective compounds. Protein-detected 
NMR methods can be implemented to provide critical 3D structural information in a 
timely manner to advance compounds through the fragment hit-to-lead stage. NMR 
offers broad capabilities that can suit the type of information needed. Protein based 
NMR methods compares the changes in the NMR parameters of the protein 
resonances in the presence and the absence of compounds. Such methods are not 
only capable of detecting the ligand binding but also provide structural information on 
where a ligand binds on a protein. Protein-detected experiments usually require 
isotope-labelled (15N-labelled or 15N/13C labelled) target protein at higher 
concentrations (0.1 - 1 mM), but can afford high-resolution structural data about the 
protein and the complex. Unfortunately, there is an upper size limit for proteins (30-
60 kDa, depending on the isotope labelling and the spectrometer) whose resonances 
can be observed and assigned by NMR.35-37  
 
Basic concepts for Protein detected NMR methods 
Isotope Labeling 
As the NMR phenomenon relies on the existence of nuclear spin, nuclei with 




For study of biomolecules, the most important nuclei are with spin quantum number, I 
= 1/2 are 1H, 13C, 15N, 19F and 31P. For proteins, the overlap caused by the number of 
1H resonances can be resolved by using heteronuclear correlation NMR methods 
(e.g. 1H-15N and 1H-13C HSQCs) achieved by the isotopic enrichment of nitrogen and 
carbon isotopes in a protein sample. Another important nucleus often employed in 
protein sample preparation is the deuteron, 2H. Replacing protons with the deuterons 
in a protein slows down the relaxation process and simplifies the NMR spectrum by 
reducing the proton density.  
Resonance Assignment 
 The prerequisite to any detailed protein-detected NMR study is the resonance 
assignment of the target protein. The resonance assignment refers to associating 
each resonance signal in a NMR spectrum to a specific nuclear spin. 
Multidimensional NMR experiments allow carrying out the backbone and side-chain 
assignment procedure by making through bond connections between the protons, 
nitrogen and carbon atoms, thereby linking all the atoms of the entire protein amino 
acid chain. An example of an assigned 2D [1H, 15N] HSQC spectrum of N-terminal 
ATPase domain of Hsp90 in which each resonance signal is associated to backbone 
nuclei (1H and 15N) of an amino acid residue in the protein sequence. This work was 
carried out in Chapter 4 of the thesis and HSQC spectrum with assignments is shown 
in Figure 2. The combination of 15N, 13C and 2H isotope labeling has expanded the 





         Figure 2. A 2D [1H,15N] HSQC spectrum of N-terminal ATPase domain of Hsp90 
displayed with backbone (1H and 15N) resonance assignments.  
 
The following sections describe various NMR methods that are capable of 
delivering 3D structural information on a protein ligand complex and also mention 
some recent developments in NMR that will give an overview of the research work 
performed in this thesis. 
 
Low Resolution Structural Information by Protein Observed NMR  
Advancing fragment hits with high micromolar to low millimolar binding 
affinities can be achieved efficiently if there are readily available 3D structures, X-ray 
or NMR, of the target protein and fragment hits. One particularly powerful and 
efficient method to map the ligand binding site at low resolution is through the use of 
NMR based chemical shift perturbation (CSP) data. The CSPs are typically obtained 
using a heteronuclear single quantum coherence spectroscopy (HSQC) experiment. 




The [1H-15N HSQC] spectrum of a protein contains resonances which 
correspond to the amide group of each amino acid residue except proline. Of all the 
different NMR parameters that change upon complex formation, CSPs are easiest to 
measure and are routinely employed to determine the binding location of the ligand. 
When a ligand is titrated, the amide group of amino acids within the protein that are 
close to the ligand will experience a change in their local chemical environment. This 
change (a CSP) is translated by a shift in the position of resonance signal for the 
respective amide group of the amino acid. A chemical shift map is generated which 
represents CSPs in a quantitative manner (the combined magnitude of 1H and 15N 
chemical shift differences for an affected residue into one parameter). This map 
allows identifying those amide groups whose environment is most affected due to the 
binding of a ligand. The map will also include those residues that are indirectly 
affected by ligand induced changes in the protein. These CSPs result mainly from the 
increased sensitivity of amide groups to pH and/or small changes that occur in the 
hydrogen bonding patterns of protein backbones upon ligand binding. If a three 
dimensional structure (X-ray or an NMR structure) and resonance assignments for 
the target protein are available, CSP mapping will show a clear surface patch of 
affected residues on to the protein structure. This can become a reliable indicator of 
the binding location of a ligand.36,37,43  
The CSP data usually shows clearly where a ligand binds to the target but 
structural information obtained by such an approach is often of low resolution and not 
of sufficient detail to calculate precisely the orientation of a ligand in the binding site, 
the level of detail that would be obtained by a complete structure determination of the 
protein –ligand complex.  Still, there is valuable information, and using the CSP 




in a docking program) can be a first step towards utilizing shift information for a 
protein–ligand costructure.62,63 Many computational programs have been 
implemented to localize a ligand binding site based on purely on the CSP analysis. 
McCoy and Wyss have developed a program j-surf based on the fact that since many 
drug molecules have aromatic rings, chemical shift perturbations are in part caused 
due to ring current shifts induced by ligand. By quantifying the spatial dependence 
of ligand ring current effects and local magnetic fields of the neighboring spins, ligand 
binding site on the protein can be accurately characterized.43,63,64  
A nice extension of chemical shift mapping called “SAR (structure-activity 
relationships) by NMR” has been developed by Fesik and co-workers.65 In this 
approach a library of fragments can be screened to identify those molecules that bind 
to two distinct but neighboring binding locations. These weakly binding molecules (or 
their analogs) can be linked into one that binds with much more higher affinity to the 
protein. This approach was successful in the finding of high affinity small molecule 
inhibitors of drug targets like BACE-1, FKBP, stromelysin, urokinase and many 
more.20,23,65  
 
High Resolution Structural Information on Protein-Ligand 
Complexes by NOEs 
NMR has become a firmly established method for determining the three 
dimensional structures not only of proteins but also of protein-protein, protein-nucleic 
acid and protein-small molecule complexes. The focus in this section is to introduce 
recently developed NOE based applications of NMR to obtain structural information 
on the location of the binding site and the conformation of the bound ligand.  




use of Nuclear Overhauser Enhancement (NOEs) derived distance restraints. 
Structures of proteins up to 20-30 kDa and protein-small molecule complexes can be 
determined successfully by NMR. NOEs provide a mechanism for both inter- and 
intramolecular magnetization transfers. The magnitude of the NOE enhancement 
between two nuclei spins is inversely related to the internuclear distance (r-6) 
between them. Therefore, NOE related experiments have been widely used for 
determining three dimensional structures of protein and protein–ligand complex as 
well as for deriving dynamic information for the protein-ligand interactions.43,36,37,66  
 
trNOEs, ILOEs and INPHARMA 
One of the ways to obtain the conformation of the bound ligand is by 
measurement of transferred NOEs (trNOEs).66 Protein targets have long correlation 
times due to large molecular weight. This allows rapid build up of NOE and extensive 
spin diffusion. By contrast, ligands are small molecules and have slow NOE buildup 
and negligible spin diffusion. This implies that if a NOESY experiment is carried out 
on a protein-ligand complex, in the presence of excess amount of ligand, NOEs 
within the free ligand develop very slowly, whereas NOEs within the bound ligand 
develop much more rapidly as it is in complex with the protein. The exchange of the 
ligand between the bound and free state will produce free ligand (with intense signals 
and chemical shifts at the positions of free ligand) displaying NOEs characteristic of 
the bound state. This is a very useful experiment, since it provides conformational 
information on the bound ligand but the information is measured from the easily 
observed and assigned free ligand signals, and is unambiguous.67 Clear advantages 
of this approach include 1) no requirement of prior information about the target 




spectral analysis as the observed ligand resonances are of much higher intensity 
compared to the protein resonances. This is due to presence of ligand concentration 
of at least 5-10 fold excess to that of the protein. Another experiment, also called an 
ILOE (interligand overhauser effect) relies on the transfer of the magnetization 
between two nuclei on different ligands which are known to occupy adjacent pockets 
on the protein. ILOEs were demonstrated first for a ternary complex of coenzyme A, 
chloramphenicol and chloramphenicol acetyltransferase.69,70 Sledz et al. have 
demonstrated the ILOE approach in fragment based inhibitor design.70 The main 
limitation of ILOE experiments is that magnetization transfer pathway caused by spin 
diffusion to protons of the protein (ligand1-protein-ligand2 instead of ligand1-ligand2) 
might cause two ligands to appear closer than is in reality. Hence the distance 
restraints obtained by ILOE measurements should be treated with caution otherwise 
they may lead to inaccurate structural information.37   
  In contrast to trNOE and ILOEs, a method which uses spin diffusion as a way 
to determine the relative orientation of two competing ligands in the binding site is 
INPHARMA (Interligand NOEs for PHARmacophore MApping). Here, the cross-
relaxation (magnetization of two different spins that are close (< 5 Å) to each other) is 
transferred via spin diffusion between ligand A and protein protons when ligand A is 
bound. When ligand A dissociates and ligand B binds in the same binding site, the 
magnetization is transferred from protein protons to ligand B. In this way structural 
information on one of the ligands bound to the protein can be obtained provided the 
structure of the other ligand is available.71 It should be realized that NOESY 
experiments such as trNOEs, ILOEs and INPHARMA are only applicable when the 





The clearest information on the binding site and orientation of the ligand can 
be obtained by direct observation of the resonances of the bound ligand. When 
isotopically labeled protein or a ligand is available, ligand and protein resonances can 
be observed separately by measurement of isotope-edited or filtered NOESY 
experiments. These experiments take advantage of the presence of natural isotopic 
abundance of the ligand and can be applied to protein-ligand systems that are in both 
fast- and slow-exchange regimes. Intermolecular NOEs are observed by observing 
one proton dimension which is filtered to protons attached to the 12C to observe 
ligand resonances and other proton dimension which is 13C edited to select for 
protein resonances.  The structure calculations can be performed using the distance 
restraints obtained from intermolecular NOEs between the complex, if the 3D 
structure of protein is known.36,37,43 
Despite its promise, it is to be realized that NMR structure determination 
process remains nontrivial as well as laborious and time consuming. It requires 
acquisition of a suite of multidimensional NMR experiments. It could take about 1-2 
months to obtain a complete 3D structure of a protein-ligand complex provided other 
considerations like sample preparation and stability are optimized.  It is also to be 
realized that the application of NMR is usually constrained due to molecular weight 
limit of the target protein. The NMR spectra for large proteins typically are of poor 
sensitivity (broader spectral resonances caused by faster relaxation properties) and 
resolution (higher spectral complexity arising from the increased number of nuclear 
spins). Recent adaptations such as (a) the development of cryogenically cooled NMR 
probes, (b) protein deuteration which result in narrower resonances, (c) 
implementation of TROSY (Transverse relaxation-optimized spectroscopy), 




NMR signal by selective 13C labeled methyl group labeling of isoleucine, leucine and 
valine groups (caused by the long T2 relaxation times exhibited by the methyl groups) 
and (e) advances in paramagnetic NMR have partly addressed the limitations 
imposed by higher molecular weight proteins.36,37 
 
Paramagnetic NMR 
  Paramagnetic based relaxation enhancement is a technique that is based on 
the interaction of an unpaired electron with a nearby nuclear spin. The electronic 
relaxation time,  (the longitudinal relaxation time of the unpaired electron spin) is 
much shorter than for protons and typically ranges from microseconds down to 
picoseconds. There are two ways in which paramagnetic effects can be observed on 
the nuclear spin. One is from isotropic paramagnetic centers which give only an 
increase in the transverse relaxation rate (PRE) of nuclei. The other is from 
anisotropic centers that cause a shift in the resonance of the nuclei (Pseudo Contact 
Shifts, PCS).  
Paramagnetic Relaxation Enhancement (PRE) 
Paramagnetic centres with slow electronic relaxation cause strong nuclear relaxation 
and thus broadening of the resonance signal. This is called paramagnetic relaxation 
enhancement (PRE).37,74 Paramagnetic effects are measured by differences between 
the NMR spectra of a target molecule bound to paramagnetic probe and bound to 
diamagnetic probe. A paramagnetic center containing an unpaired electron, e.g. a 
nitroxide radical, is attached via a disulphide linkage to an engineered cysteine 
residue and invariably causes broadening of the resonances due to the enhanced 
transverse relaxation rate (T2) of the nuclei in close proximity. The PRE effect is 




unpaired electron and the nuclear spin.  
Pseudocontact Shifts (PCS) 
The anisotropy of the paramagnetic effect is described by the magnetic 
susceptibility tensor, and causes pseudocontact shifts. The PCS is angle/orientation 
dependent and proportional to r-3 distance. The r-3 distance dependence of the PCS 
in comparison to the r-6 dependence of the PRE, allows PCSs to be measured for 
nuclear spins that are far away (> 20 Å). The paramagnetic effects can be converted 
into distance restraints which can be used to dock the binding partners. This enables 
new possibilities for the analysis of protein-protein and protein-small molecule 
interactions.75  
 
Application of Paramagnetic NMR Methods  
The application of paramagnetic NMR in structural biology is increasingly 
becoming important as it can provide different levels of structural information.  
 
Application of PRE to Study Ligand Binding  
Paramagnetic NMR can be used to obtain low resolution information on the 
binding site of the fragments as demonstrated by Janke and co-workers.76 They have 
demonstrated an PRE-based approach called  SLAPSTIC (spin labels attached to 
protein sidechains as a tool to identify interacting fragments) to obtain 3D structural 
information. In this approach, paramagnetic, organic radicals such as TEMPO, are 
covalently linked to the side chain of specific amino acids (lysine, cysteine, 
methionine, histidine or tyrosine). This approach uses a spin labeled compound as a 
first-site ligand. Screening of this complex allows identification of compounds that 




drug discovery and optimization process, because linking of two compounds that 
bind in proximity can result in compounds with significantly higher affinity. The 
principal advantages for this approach are its robustness to identify second site 
binders, low protein requirements and high spectral sensitivity.However, SLAPSTIC 
requires considerable knowledge of the protein 3D structure, confirmation that spin 
label attachment does not compromise the binding site on the protein target and the 
relaxation enhancement only results if two ligands bind simultaneously to the protein 
target and at neighboring sites.76 A further extension is also presented in chapter 3, 
where a PRE based approach is developed for a GTPase to obtain 3D structural 
information on the binding site of biologically active compounds. 
 
Application of PCS to Study Ligand Binding  
Recently, a paramagnetic NMR based approach has been developed by our 
group in which 3D co-structures of small molecule bound to a protein can now be 
readily determined using paramagnetic PCS data.77 Here, a co-structure of the target 
protein, FKBP12 bound to initial fragment hit was obtained using PCS datasets. 
These structures allowed determination of the binding site and the orientation of the 
ligand. The PCS-driven result was then compared and found in close agreement with 
independently NOE-derived structure of the same FKBP12-ligand complex. A major 
advantage of this method is no labeled protein is required. Thus, it can be applied to 
larger molecular weight protein targets that are suboptimal for the resonance 
assignment procedure.   
 
Selective Isotope Labeling of Methyl Groups 




have been strongly connected to the development of optimal isotope labeling 
techniques. Of particular interest are the experimental protocols that have been 
developed to obtain protein samples that are deuterated but selectively protonated at 
specific sites (amide protons and certain methyl group containing residues). There 
are several advantages of using methyl groups as probes, (i) the residues containing 
methyl groups occur frequently throughout the protein sequence and at ligand 
binding sites81 (ii) methyl groups have favorable NMR relaxation properties so that 
even for protein targets with high molecular weights, NMR spectra are of higher 
sensitivity and resolution80 (iii) data interpretation is simplified due to less overlap of 
the resonances in the NMR spectra and (iv) methods to produce ILV selectively 
labeled samples in E. coli are robust and economical.79,80  
 
Applications of Methyl Group Labeling   
Tugarinov and co-workers80 have shown that by selective labeling it is 
possible to obtain sidechain methyl and amide resonance assignments and calculate 
the global fold of a protein, Malate Synthase G (MSG), which has a molecular weight 
of 82 kDa.80 The global fold of MSG was calculated using NOEs between methyl-
methyl, methyl-amide and amide-amide groups. In such an application Hajduk and 
co-workers81 have shown that the methyl groups of Leu, Val and Ile residues in a 
protein can be selectively 13C labeled and 13C/1H chemical shift perturbations can be 
monitored to detect ligand binding. Both these examples show that the selective 
labeling procedure extends the size of the molecular systems that can be 
investigated by NMR and methyl groups can be used as probes to detect ligand 
binding. To broadly extend the approach to study ligand binding by selective labeling, 




of all methyl containing residues (leucine, valine, isoleucine methionine, threonine 
and alanine) in a protein. This type of labeling achieves a better coverage of the 
binding site of the protein. However, it should be noted that methods to produce 
selectively labeled protein samples are currently applicable using E. coli.  
In order to increase the efficiency of utilizing methyl groups as probes to detect 
ligand binding, steps to automate the methyl group assignment procedure have been 
undertaken. These methods are either based on the availability of the crystal 
structure of the protein and make use of the NOESY experiment or paramagnetic 
NMR to define the methyl group network. Appropriate paramagnetic tags are placed 
on the protein surface through engineered cysteine residues to get complete 
coverage of the PRE effects for the methyl groups within the protein structure. 
Methods also have been developed that demonstrate the use of through-space 
paramagnetic effects combined with NOESY experiments to rapidly obtain methyl 
assignments, if a crystal structure of the protein target is known. 83-87 Similarly, Otting 
and co-workers84 as well as Skinner and co-workers87 have developed tools that use 
paramagnetic pseudo-contact shifts to directly obtain ILV sidechain assignments.78,83-
87   
Various academic groups have demonstrated that selectively isotope labeled 
groups of the protein can be used to collect intermolecular NOEs with its binding 
partner in order to obtain structural information. However, these methods have one of 
the following limitations: 1) they require prior information of the binding site so as to 
appropriately label residues on the target, 2) resonance assignment is based on the 
pattern of observed CSPs induced by ligand binding 3) requirement for large number 
of intermolecular NOEs and/or 4) extensive computer calculations to generate 




to generate protein-ligand structures that is based on a combination of selective 
amino acid labeling and collection of only few intermolecular NOEs is presented in 
chapter 3 of this thesis.89 
  
Scope and Outline of Thesis 
NMR methods that provide a better understanding of protein-ligand 
interactions are critical in the early stages of drug discovery. Traditional NMR 
methods used to obtain 3D structural information tend to be slow and labor intensive. 
The main area of this thesis was to develop and implement efficient solution based 
NMR approaches that provide 3D structural information on the protein-ligand 
complexes and could be readily applied in early stages of preclinical drug discovery. 
Below is the brief overview of all the chapters that describe the research work 
performed in this thesis.  
  Chapter 2 describes the application of TINS screening to discover small 
molecule ligands that bind the ETS-domain of TEL (TELETS). TEL is a DNA binding 
protein and involved in the transcriptional regulation of the other proteins and a 
therapeutic target for tumorigenesis.90-92 Biochemical and structural analyses were 
performed using protein observed NMR, SPR (Surface Plasmon Resonance) and 
gel-shift assay to demonstrate DNA binding activity of TEL. Three fragment hits 
generated by the TINS methodology were then validated by protein observed NMR to 
obtain low-resolution structural information on the binding site of these fragments. 
Interestingly, these primary hits occupy the same binding spot on the protein as the 
DNA and when used at high concentrations in gel-shift assay have the potential to 
disrupt the DNA binding capability of TELETS. These novel fragments represent 




   In Chapter 3, a fragment based drug discovery approach is applied to Rit1 
GTPase, a validated target for Rheumatoid Arthritis.93,94 In this chapter the results 
obtained from fragment based screen, crystallization, analoging, hit development and 
structural study on the most potent compound are discussed. One main obstacle in 
the project was to obtain 3D structural information on the Rit1-ligand complexes. 
Substantial efforts to crystallize the complex were not successful due to low solvent 
content of the protein crystals and cracking of protein crystals in the presence of the 
most potent compound. To address this issue, a solution based approach was 
necessary and a paramagnetic NMR based approach was sought, whereby a spin 
label was introduced on GDP. Paramagnetic studies using the GDP-spin label 
followed by docking calculations propose a novel mechanism by which the 
compound inhibits GDP-GTP exchange of Rit1. The PRE based method in this 
chapter presents an alternative to obtain binding site information on the protein-
ligand complex when other high resolution techniques fail.  
 In Chapter 4, a solution NMR method was developed to obtain 3D structures 
of a protein-small molecule complex in rapid and efficient manner. The NMR method 
makes use of a small molecule that binds in the ATP binding pocket of the N-terminal 
domain of Hsp90 that was discovered by TINS NMR screening.40,80,95 The main goal 
was to use this protein-ligand system to develop an efficient way to obtain 3D 
structural information on protein-ligand complexes. This chapter demonstrates how a 
combination of selective methyl group labeling, standard NMR experiments and 
computational docking can be used to rapidly determine the 3D structure of a small 
molecule bound “weakly” to a protein target. The approach requires only a sparse set 
of intermolecular NOEs and is an alternative to traditional NMR approaches that 




 Finally, concluding remarks about the research work in this thesis are 
presented in Chapter 5. Each molecular system investigated is overviewed and the 
different approaches that were employed are presented. The prospects and possible 
applications of the study are also discussed.  
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The discovery of small molecule ligands help in the design of inhibitors against a 
protein target involved in a particular disease. Here, we present a study in which we 
have applied a fragment based screen against a potential tumor angiogenesis target, 
TEL. TEL and its associated network proteins are involved in control of the 
development of blood circulatory system. TEL is a transcription repressor that 
functions through bind of its C-terminal ETS domain to DNA which sterically blocks 
the access of transcription factors to the promotor. The development of specific 
inhibitors which would disrupt DNA binding is desirable as this would lead to loss of 
downstream signaling cascade. Here, we have characterized the DNA binding of 
TEL-ETS domain using protein-observed NMR, gel retardation and surface plasmon 
resonance. Of a number of fragment hits, three were further validated using protein-
observed NMR. Chemical shift mapping revealed that these fragments share the 
same binding interface as the DNA. Furthermore, we see that the presence of 
fragments at a high concentration in the gel retardation assay disrupts the DNA 
binding capability of TEL. These fragments provide valuable starting entities to 
develop potent compounds against TEL with a novel mechanism which in turn could 











  Activation and repression of the transcription of eukaryotic genes during cellular 
development and/or response to extracellular stimuli, is a highly organized event 
involving assembly of many protein complexes at promoters and enhancers.1 
Amongst various signal dependent transcriptional regulators, the ETS-family of 
proteins is one of the largest known involved in proliferation, differentiation and 
tumorigenesis.2 ETS1 is the founding member of this family and the name “ETS” is 
derived from the avian erythroblastosis virus E26, which carried “v-ets' (E twenty-six) 
oncogene.3 Many of the members are known to activate transcription but the ETS 
family also includes transcriptional repressors.2 One of the known repressors is TEL 
which was identified due to its fusion to the 3' -half of the gene encoding the platelet 
derived growth factor β receptor in chronic myelomonocytic leukemia.4 The 
transcriptional repression may involve one of the following mechanisms. The 
repressor may act by 1] directly binding to the activation domain of a transcriptional 
activator, 2] by displacing an activator from activation site, 3] indirectly by altering the 
chromatin structure and accessibility of a region on the DNA or 4] interfering with the 
basic transcriptional machinery.2   
  Structurally, TEL possesses an evolutionarily conserved ETS-domain which binds 
DNA sequences with a GGAA/T core motif.5 In fact, most of the ETS proteins 
recognize a consensus 5' -GGAA/T-3' motif within the context of a 9- to 10-bp DNA 
sequence. 3,6,7 TEL also carries a PNT (Pointed or SAM) domain at the N-terminus 
which is observed to influence not only the DNA binding but its interaction with other 
regulatory proteins. The PNT domain of TEL is capable of forming a stable head to 
tail polymer and hence most likely the full length TEL also has the ability to 




also results in the constitutive activation of the tyrosine kinase activity of fusion 
protein TEL-ABL, TEL-platelet derived growth factor β receptor and TEL-JAK2, a 
property that is essential to their transforming and leukemogenic properties.4,8-11 On 
other hand, the role of the ETS-domain of TEL, here after refered as TELETS, in DNA 
binding is influenced by an autoinhibitory mechanism in which a flanking C-terminal 
helix sterically blocks the monomeric ETS-domain. A conformational change is then 
likely to be necessary in order to carry out DNA binding. It has also been proposed 
that TEL displays a conformational equilibrium between two structural states 1] 
where the C-terminal helix is in the inhibitory conformation and 2] where it is in an 
uninhibited conformation thus not interfering with the DNA binding.4   
    In addition to structural features, the functional importance of TEL is realized by 
the fact that it is also a therapeutic target to inhibit tumor angiogenesis. TEL is 
indispensable for endothelial sprouting and normal development of the Danio rerio 
blood circulatory system. TEL acts by regulating the transcription of various 
angiogenesis inhibitors and executes its function in conjunction with CtBP (Carboxy 
terminal binding protein). The complex of TEL-CtBP helps in the conditioning of the 
endothelial cells for angiogenesis. This conditioning is achieved by regulating the 
balance between stimulatory and antagonistic sprouting cues. One of the plausible 
hypotheses is also considered where the interaction of CtBP with the PxEIM motif of 
C-terminal helix of TEL leads to increased DNA binding affinity of TEL. By this way, 
TEL is able to block the transcription of other essential proteins thought to control the 
development of blood vessels to tumorigenic tissues. Clearly, the development of 
specific inhibitors that would either disrupt the DNA or CtBP binding of TEL would 
open the way for the development of therapeutic strategies to inhibit pathological 




  In this work we have demonstrated the binding of the TELETS domain to DNA by 
protein observed NMR, a gel retardation assay and surface plasmon resonance. With 
a view to find small molecule inhibitors for TELETS that would potentially disrupt the 
DNA binding and hence downstream signaling cascade, we have applied a fragment 
based screen to generate a set of primary hits. In fragment based drug discovery 
(FBDD) approach, a larger portion of chemical structure space is explored with a 
smaller number of compounds. Since the fragments are small and much simpler than 
drug-like molecules, the fragment methodology enables to discover molecules which 
bind more efficiently on the protein surface. A fragment based screen was carried out 
using TINS screening of a fragment library consisting of commercially available 
compounds.13-16 Three fragments hits from the screen were further validated using a 
protein observed NMR approach and gel retardation assay. Using chemical shift 
mapping through protein-observed NMR experiments, we were able to obtain the 
binding site of the fragments. Interestingly, the binding surface for the DNA and 
fragments mapped onto the 3D structure of TELETS available in the protein data bank 
(PDB 2DAO) revealed that the fragments bind at a similar binding interface as the 
DNA. Furthermore, we have shown that the presence of high concentration of the 
fragments in the gel retardation assay disrupts the DNA binding capability of TELETS 
domain.13  
Results   
Target immobilized NMR screening of TEL-ETS domain: 
  We employed TINS (Target Immobilized NMR screening) screening as a primary 
screen for hit generation on TELETS domain.14 TELETS and the reference protein, Akt 
PH domain were purified and immobilized via primary amine coupling as described in 




because it represents a typical protein surface, yet devoid of any specific small 
molecule binding sites. Further, the use of reference protein in TINS eliminates very 
weak and non-specific binders which otherwise might lead to false positives in the hit 
identification process.  The functionality of immobilized TEL was determined by 
repetitive injection of a fragment that appeared as a hit during initial part of the 
screening procedure.15  
     
 A fragment library consisting of 1364 commercially available fragments was 
screened against TELETS.16 The fragment library was screened by repeated cycles of 
injection of various mixes of fragments, which consisted of 3 to 5 compounds per 
mix, into both the cells of a dual-cell packed with immobilized TELETS domain and the 
reference protein. After a mix was injected, the flow was stopped and the NMR data 
was acquired. TINS NMR experiments consisted of using spatially selective 
Hadamard pulse sequences and the results were analyzed as described.14,15 The 
fragments were washed out prior to the next injection of a new fragment mix. The 
binding of a fragment to a protein molecule immobilized on the solid support causes 
broadening of the resonances from that fragment. As a result a fragment binding 
specifically to TELETS domain could be detected by simple reduction in the height of 
all the NMR signals from that fragment in the presence of  TELETS relative to that in 
the presence of a reference protein (Figure S1). The fragment screen resulted in the 
identification of 103 unique hits for TELETS domain resulting in a hit rate of 7.5%. 
Sequential Backbone resonance assignments 
  The sequential backbone assignment for the TELETS was achieved by acquiring 
standard triple resonance NMR experiments. Although the solution structure of the 




assignments that are available. The sequential backbone assignments were obtained 
by correlation of Cα and Cβ chemical shifts of i and i-1 residues to the amide 1H and 
15N resonances using HNCACB, CBCAcoNH, HNCA and HNcoCA spectra. Overall, 
the spectra were of good quality and 82% of the backbone sequential assignment 
was obtained.   
Characterization of TEL-DNA binding   
  The DNA binding of TELETS was characterized using three different approaches. We 
have used protein-observed NMR, gel-retardation and surface plasmon resonance.  
DNA binding by Protein-observed NMR 
   We employed a frequently used protein observed 2D-heteronuclear single quantum 
coherence (HSQC) NMR method wherein increasing concentrations of the 
compound is titrated into uniformly 15N labeled protein and changes in the NMR 
spectra are followed in presence and absence of the compounds.17,18 In order to 
assess the DNA binding capability of TELETS , an oligonucleotide  consisting of 10 
base pairs containing the TELETS recognition site was titrated into the 15N isotopically 
labelled TELETS. A short oligo nucleotide sequence (5’-ACAGGAAGTG-3’) was 
purposely chosen for the NMR study. The oligonucleotide was titrated at three 
protein to oligo ratios of 1:2, 1:4 and 1:6. Significant chemical shift perturbations 
(CSPs) are observed in the 2D [1H,15N] HSQC NMR spectrum upon addition of the 
DNA as seen in Figure 1.17,18 It is also observed that at a protein to oligo ratio of 1:4, 
the binding is saturated as the position of the CSP does not change beyond that 
concentration. The upper limit for the binding affinity is estimated to be around 80-
100 µM. The availability of the sequential backbone assignment of the protein 
allowed us to map the specific residues involved in DNA binding onto the available 




interface of TELETS domain based on the observed CSPs. Figure 2A shows the 
binding map of all the residues that show significant chemical shift perturbations in 
the presence of DNA. The key protein residues involved in the binding are I40, L46, 
G51, K54, S65, R66, Y71, Y72, R84, F87, T101, L112 and S113. The numbering of 
the residues here is same as PDB 2DAO. Overall, the protein-DNA complex seems 
to be in the fast exchange regime on an NMR time scale. Some broadening of the 
resonance peaks is observed when concentration of DNA is gradually increased.  
 
Figure 1. The characterization of DNA binding using protein-observed NMR. [A] The overlay 
of the 2D [1H, 15N] HSQC spectra of TELETS in the absence of DNA (black) and in the 
presence of the DNA (red). The concentration of the protein used was 60 µM. [B] The 
concentration dependent chemical shift perturbation observed for residue R84 in the 
presence of the increasing protein to DNA ratios is shown. In black is the free protein. The 







Figure 2.  The determination of protein-DNA binding interface. A] Chemical shift mapping of 
the residues involved in the DNA binding as obtained by titration of increasing concentrations 
(Δδ, (CSPdifference) > two times standard deviation + Δδavg) of the DNA into 15N labeled TEL 
and observed by 2D HSQC NMR. The mapping of the residues was performed using the 
available structure of TEL (2DAO) B] The electrostatic surface potential (blue-positive 
charge, red- negative charge) of the protein. The figure was created in PyMOL 19 
 
Gel retardation assay 
   The DNA binding to TELETS was characterized using a gel retardation assay.  To 
investigate DNA binding using gel retardation, increasing amounts of the protein 
were titrated into a 32P-labelled- DNA oligonucleotide containing three ETS-binding 
sites (5’-AAACAGGAAGTGAGAACAGGAAGTGAGAACAGGAAGTGG-3’). 
Subsequently, DNA binding was analyzed using a gel retardation assay. As seen in 
Figure 3, the migration of the labeled oligonucleotide was retarded indicating that the 
protein binds to the DNA. The DNA binding of the protein is only visible upon titrating 
higher concentration of protein indicating that TELETS on its own binds comparatively 
more weakly than the full length TEL harboring the N-terminal PNT-domain.4 It is also 
observed in Figure 3 that two bands (a lower band representing unbound 
oligonucleotide and a higher band representing protein-DNA complex) are seen for 
DNA to protein ratios between 1:40 to 1:200. To quantitate the binding affinity of the 








Figure 3.  The DNA binding by TELETS using gel retardation assay. TELETS was titrated into a 
constant amount of 32P labeled oligonucleotide at indicated ratios. The position of the DNA-
protein complex is denoted by arrow. The retardation of the DNA can be clearly seen upon 
titrating higher concentration of the protein, indicative of the complex formation. 
 
Surface Plasmon Resonance 
  The characterization and affinity determination of DNA binding to TELETS by SPR 
was achieved by immobilizing the protein on the chip surface to an immobilization 
level of around 9000 RU. Following the immobilization, increasing concentrations of 
the same oligonucleotide used in the gel retardation assay (with three recognition 
sites) were injected in a single cycle manner. The binding response at each 
concentration was then plotted against the DNA concentration and KD was 
determined by a 1:1 binding model using GraphPad Prism software (Figure 4). The fit 
yielded a KD of 1.9 µM. The affinity appears to be tighter than that estimated from the 
NMR titration. This difference in the KD is likely due to the presence of three  -GGAA- 
recognition sites on the oligonucleotide used in the SPR assay compared to one in 






Figure 4. The determination of the DNA binding affinity of TELETS using SPR.   [A] The  
sensorgram obtained by single cycle injections of increasing concentrations of DNA (1 µM, 5 
µM, 7.5 µM, 10 µM, 15 µM) onto immobilized TELETS . The green line corresponds to the 
background response.  [B] Shows the graph obtained by a fit to 1:1 binding model as 
analyzed by GraphPad prism software and exhibited a KD of 1.9  µM.  
 
Validation of fragment hits by HSQC 
The validation of fragment binding to TELETS was carried out by protein observed 
NMR using HSQC experiment (described earlier). The main goal at this stage was to 
validate a limited number of fragments that would be easier to follow-up by medicinal 
chemistry (Fragments for which commercial analogs were available and those that 
can be easier to undergo synthetic chemistry). Three fragments as shown in Figure 5 
were selected from a set of hits for this purpose. The resulting CSPs observed upon 
addition of the fragments were then mapped onto the available TELETS solution 
structure (PDB 2DAO). Interestingly, a similar region of TELETS is affected upon 
addition of all three fragments. As seen in Figure 6, CSPs for these fragments are 
localized mainly on the protein surface which is common to DNA binding (Figure 3A). 
The key residues that show significant chemical shift perturbations are N44, R56, 
K63, R66, A67, R69, I76, F87, T101 and S113 for fragments 1 and 2. For fragment 3, 
















the key residues that gave significant chemical shift perturbations were V15, G51, 
S66, I77, E80, F87, T101, L112 and S113.  
 
 
Figure 5. The chemical structures of fragment hits that were employed for follow-up studies 
after the initial TINS screen on TELETS. Fragment 4 is not a hit and was used as a control 
for gel retardation assay.16 
 
 
Figure 6.  Chemical shift mapping of the protein residues involved in fragment binding to 
TELETS. The chemical shift perturbations (in red) caused by the presence of the indicated 
fragment hit as determined by [1H,15N] HSQC NMR are mapped onto the available PDB 
structure of TELETS  (2DAO). The most significant chemical shift perturbations (Δδ > two 




Disruption of the DNA binding to TELETS by fragments in gel retardation assay 
  In order to investigate the effect of fragments on oligonucleotide binding, we carried 
out gel retardation assay. First, TELETS and oligonucleotide were incubated to form a 
stable complex at a DNA to protein ratio of 1:200. Subsequently, fragments 2 and 3 
were added and the reaction mixture was further incubated for 2 hrs at room 
temperature. The reaction mixture for fragment 1 showed signs of precipitation and 
as a result was not considered for further characterization. As a control, a fragment 
that did not appear as a hit in the TINS screen was also used. As seen in Figure 7, in 
the presence of 10 mM of the fragment, DNA binding to TELETS is significantly 
reduced. In the presence of control fragment, the DNA binding is not affected 
indicating the specificity of the fragments that bind to the TEL-ETS domain.  
 
Figure 7. Disruption of DNA binding observed in the presence of validated fragment hits 2 
and 3. The final concentration of the respective fragment in the reaction mixture is indicated. 
Fragment 4 was not a hit in the TINS screen and was used as a control. The asterisk (*) 
indicates a reaction without added fragment with equal percentage of DMSO. The disruption 
of oligonucleotide binding is clearly seen at fragment concentrations of 10 mM and 
comparatively less at a lower fragment concentration (5 mM).  
 
Discussion and Conclusions 
   Here we report a study that focuses on the interaction of small molecules with 
TELETS. To date there are no known inhibitors that disrupt the TEL-DNA binding. To 
identify potential fragment hits, we have applied a fragment based screen by NMR 




fragments rather than drug-sized molecules is that a dramatically larger portion of 
chemical structure space is explored with a smaller number of compounds.  
  In the study presented here, the interaction of the DNA oligonucleotide with TELETS 
was analyzed using protein observed NMR, gel retardation assay and SPR. The 
binding affinity for the DNA was determined to be 1.9 µM. To find small molecule 
inhibitors that would target the DNA binding site, it would be first necessary to obtain 
a structural basis for the binding of TELETS -DNA complex. We have used protein-
observed HSQC NMR to obtain low resolution information to define the DNA binding 
interface of TELETS. The CSP data obtained from the [1H,15N] HSQC experiment 
clearly demonstrate that DNA binding to TELETS is mediated by a highly positively 
charged protein interface. Of a number of fragments hits discovered from the TINS 
NMR screen, three fragments were further selected from medicinal chemistry point of 
view (fragments that can be easily chemically modified). These were further 
characterized and validated for binding using protein-observed NMR experiments as 
described earlier. Interestingly, the ligand induced chemical shift changes clearly 
illustrate that all three fragments bind at the DNA binding interface. The commonality 
of the binding site between the fragments and the DNA is also reflected in the gel 
retardation assay. The presence of fragments 2 and 3 at high concentrations in the 
assay caused significant disruption of TELETS -DNA binding. The use of high 
concentrations was necessary and indicates that the fragments weakly interact with 
TELETS. This is not surprising as these are starting points and not elaborated 
compounds.  
Inhibitors that would specifically disrupt DNA binding should lead to loss of the 
downstream signaling cascade and influence the transcription repressor function of 




the regulation of angiogenesis in tumors tissues.12 The functional inhibition of the 
TELETS-DNA complex exhibited by the validated fragments 2 and 3 in gel retardation 
assay suggests they might be starting points to develop tool compounds to enable 
further target validation studies. However, the selectivity of these fragment hits 
against the ETS- domain of other proteins and in the presence of CtBP, remains to 
be tested.  
Experimental Section 
Protein expression and purification: 
C-terminal hexahistidine tagged- TELETS (1-118 as per numbering in the PDB-
2DAO; 334-452, the numbering as per UniProt ID P41212) was cloned into pET28a 
and cultures in LB medium containing kanamycin (50 µg/mL) at 37°C in E.coli strain 
BL21 (DE3) (Stratagene). Protein expression was induced at an OD600 of 0.6 with 
0.5 mM IPTG and growth was continued for 4 hours at 30°C. The cell pellets were 
collected by centrifugation at 5000 rpm for 30 minutes. The cell pellets were 
resuspended in 50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 10 mM imidazole, 
1 mM β-mercaptoethanol and stored at -80°C. Cells were lysed by addition of 50µl 
lysozyme  (50 mg/mL) followed by incubation for 1 hour at 4°C and passing through 
French press at 1500 psig twice. The recovered lysate was centrifuged at 35000 rpm 
at 4°C for 45 minutes using a Beckman Ti35 rotor. The supernatant was applied to a 
5 mL HisTrap HP Ni2+ affinity column (GE healthcare) equilibrated in the 
manufacturer's suggested binding buffer supplemented with protease inhibitor PMSF. 
The column was washed with 50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 200 
mM imidazole, 1 mM β-mercaptoethanol and protein was eluted with 50 mM sodium 
phosphate (pH 8.0), 300 mM NaCl, 10 mM imidazole and 1 mM β-mercaptoethanol. 




of 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA and 1 mM β-mercaptoethanol.  
  
TINS NMR screening 
  C-terminal hexahistidine tagged- TELETS (334-452) was cloned into pET28a and 
expressed in E.coli strain BL21(DE3) (Stratagene). The protein was first purified on 
Ni-Hitrap FF (GE lifescience) followed by purification on Superdex G75 with buffer of 
25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA and 1 mM β-mercaptoethanol. 
TELETS (334-452) and Akt PH domain (aa 1-123) were immobilized via amine-
coupling to 500 µL Actigel-ALD resin (Sterogene) in 25 mM Hepes pH 7.5, 100 mM 
NaCl and 2 mM MgCl2 at 4°C using the coupling reagent provided by the 
manufacturer. The immobilization efficiency was above 90% and the final 
concentrations of the immobilized targets were typically in the range of 100 µM. TINS 
NMR experiments were performed on a 500 MHz Bruker NMR spectrometer using 
spatially selective Hadamard pulse sequences and analyzed as described 
previously.14-16,20,21 
 
Enzyme Mobility Shift Assay 
  The DNA binding to TELETS was detected using a gel retardation assay.  The 
indicated amount of protein was diluted in a buffer consisting of 10 mM HEPES, pH 
7.8, 2 mM MgCl2, 0.1 mM EDTA, 100 µg/mL bovine serum albumin, 15% glycerol, (0-
0.8) µg/mL poly(dI-dC) (Boerhringer Mannheim) and 2 mM dithiothreitol in a total 
volume of 15 µL. 20 fmol of the 32P-labeled DNA oligonucleotide in 5 µL was added, 
incubated on ice for 30 minutes and applied to a non-denaturing 8% Tris-glycine 
acrylamide gel containing 2% glycerol. Electrophoresis was performed at 80V for 20 




200 mM glycine. The gel was dried and radioactivity was detected using a 
phosphorimager (Biorad).    
  The three validated fragments determined as hits to TELETS domain from TINS NMR 
screening were subjected to gel shift assay analysis. The indicated concentrations of 
the fragment were added to the reaction mixture and incubated for 2 hours at room 
temperature. The amount of DMSO in the controls was matched to the equivalent 
amount in the presence of a fragment.  
 
NMR backbone sequential assignment 
Uniform 13C, 15N labeling of TEL-ETS domain was achieved by expression of 
C-terminally hexahistidine tagged TELETS (aa 334-452) in E.coli BL21 (DE3) cell 
grown in M9 minimal medium supplemented with 15NH4Cl and 13C-D-Glucose (CIL) 
as a sole nitrogen and carbon source.  The protein was purified as described above. 
The protein was concentrated down to 0.7 mM in 25 mM HEPES pH 7.5, 100 mM 
NaCl, 1 mM EDTA and 1 mM β-mercaptoethanol. In order to perform sequential 
assignment of backbone amide, the following experiments were acquired at 296K on 
a 600MHz BRUKER DMX NMR spectrometer equipped with a TXI cryo-probe; [1H, 
15N]-HSQC, HNCO, HNCaCb, CbCaCONH, HNCaCO, HNCA, and HNCOCA . The 
acquired data was processed using nmrpipe and visualized on Sparky.22,23 The 
assignment process was guided by the predicted chemical shifts calculated by 
SHIFTX in automatic assignment program MARS using PDB-2DAO as an input 
structure.24,25 
 
Chemical shift perturbation and generation of binding site 




(DE3) cell grown in M9 minimal medium supplemented with 15NH4Cl as a sole 
nitrogen source, and purified as described above. The [1H,15N]-HSQC were acquired 
at 296K on a 600MHz Bruker DMX NMR spectrometer equipped with a TXI cryo-
probe. The NMR sample was prepared in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 
mM EDTA and 1 mM β-mercaptoethanol. The typical NMR sample contained 0.130 
mM of the protein, fragments at various concentrations (see text) and 5% d6-DMSO. 
The pH of the samples was adjusted carefully within +/- 0.05 units after addition of 
the compound. During the experiment, total of 128 indirect increments with 16 scans 
per increments were acquired. The data was processed using Topspin 1.2/2.1 
(Bruker) and visualized on Sparky.23 Chemical shift perturbations in [1H, 15N]-HSQC 
were calculated based on the (Δδ > two times standard deviation + Δδavg) for change 
in 1H and 15N ppm value between in the presence and absence of a compound. The 
potential binding sites of a compound were mapped onto the surface of the TEL-ETS 
domain (PDB-2DAO) structure using chemical shift perturbation data and viewed in 
PyMOL.19  
 
Surface Plasmon Resonance studies  
 DNA binding to TELETS domain was tested using surface plasmon resonance on a 
T200 biacore instrument (GE healthcare). Initially, pH scouting was performed to 
determine the optimum pH for protein immobilization on the CM5 chip surface. 
Following immobilization of the protein to required response units (6000 RU), 
increasing concentrations of DNA were titrated in a single cycle kinetic mode. The 
buffer conditions used was 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA and 1 
mM β-mercaptoethanol + 3% DMSO. The analysis was performed using a Biacore 





The clones for the production of the protein were provided by David A. Baker (Leiden 
Univeristy Medical Centrum). Ruta K. Nachane was responsible for protein and 
compound preparations for TINS NMR screening. Johan G. Hollander helped in the 
NMR set-up of the TINS screen and Eiso AB performed the computational analysis of 
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A fragment based drug discovery approach has been used to discover 
phthalimide-based inhibitors of a novel Rheumatoid Arthritis (RA) protein target Rit1, 
a member of the Ras superfamily of small GTPases. NMR screening and a 
nucleotide exchange biochemical assay were used to discover and validate fragment 
hits with IC50’s in the millimolar range (1,2) that specifically inhibit the interconversion 
between the GDP bound “inactive form” and the GTP bound “active form” of Rit1. 
Elaboration of fragment hits yielded compounds with IC50’s of ~180 µM (16e, 17e and 
18c) in the biochemical assay. A crystal structure of the binary Rit1:GDP complex 
was solved to 2.3 Å resolution, however, it proved impossible to obtain crystals with 
any of the Rit1 inhibitors. Instead alternative, NMR-based methods in combination 
with molecular docking were employed to obtain 3D structural information on the 
ternary complex of Rit1·GDP and inhibitor 18c. The docking solutions show that 18c 
exchanges between two binding sites that lie very close to the GDP binding pocket of 
Rit1. The docked structures further reveal a novel mechanism of action, where in one 













Rheumatoid Arthritis (RA) is a chronic degenerative disease, characterized by 
inflammation and erosion of the joint structures. When not treated, it leads to 
substantial disability and pain in the joints. The onset of RA is characterized by the 
inflammation of the synovial membrane (‘Synovitis”) which correlates with increased 
expression of a specific matrix-metalloproteinase (MMP) MMP1, by synovial 
fibroblasts (SFs). Numerous treatments for aspects of the disease are available e.g. 
NSAIDS (Non-Steroidal Anti-inflammatory Drugs) to limit inflammation and DMARDS 
(Disease Modifying Anti-Rheumatic Drugs), but most of them are found to have 
limited efficacy for the treatment RA in the longer term.1 In an effort to find new 
targets with therapeutic value for RA, an siRNA screening strategy was undertaken. 
The screen uncovered a group of potential protein targets, of which a specific protein, 
Rit1, was involved in an early stage of the onset of RA (US patent 7,919,259 B2). 
Rit1 is an interesting therapeutic target as it regulates the expression and secretion 
of MMP1 leading to the onset of collagen degradation. Rit1 activity is upregulated in 
synovial fibroblasts.2 This observation suggests that inhibition of Rit1 activity could 
have therapeutic benefits for RA patients. 
Rit1 (Ras-like protein in all tissues) is a member of the Ras superfamily of 
GTPases.3 Proteins of the Ras family, which comprises more than 150 members in 
humans, are small (~25 kDa) and monomeric. Ras members function as molecular 
switches that govern a wide variety of signal transduction pathways that regulate e.g. 
cellular growth, proliferation, differentiation and apoptosis.4,5,6 GTPases carry out 
their cellular function by cycling between an inactive GDP bound form and an active, 
GTP bound form.7 Shuttling between active and inactive forms is facilitated by two 




and GTPase activating proteins (GAPs). GEFs function by catalyzing the exchange 
of GDP for GTP thereby activating the G protein. In the active form, G proteins 
interact with downstream effectors and thus propagate further signaling events such 
as transcription regulation that lead to the desired biological response. The low 
intrinsic GTPase activity of G proteins is enhanced by interaction with GTPase 
activating proteins (GAPs), that down regulate signaling activity by speeding 
conversion to the inactive form.8 Numerous studies have shown that proteins from 
the Ras family are overexpressed in about one third of human cancers and thus are 
implicated as oncology drug targets.5  
Ras GTPases undergo extensive post-translational modifications that regulate 
their interaction with other proteins, protect them from proteolytic degradation, 
facilitate association with the cell membrane or determine their subcellular 
localization and function. Previous attempts to target this family pharmacologically 
have focused mainly on inhibition of post-translational modifications such as 
farnesylation or geranylgeranylation.9,10,11 These inhibitors prevent membrane 
association of the GTPase and hence cause the loss of cellular function. However, 
the performance of such compounds in clinical trials has not been as good as hoped, 
mainly due to adverse effects and toxicity related issues.12 Many other therapeutic 
approaches such as targeting prenylation and post-prenylation modifications, 
targeting GEFs and GAPs and the functional regulation of GDP/GTP exchange are 
exciting alternatives and are reviewed elsewhere .12 
In contrast to other Ras GTPases, Rit1 lacks a known recognition signal for C 
terminal lipidation, which is necessary for membrane association.13 It has been 
reported by a number of groups that Rit1 signals to a variety of Ras responsive 




RGL3, a novel RalGEF.14 However, these studies also show that Rit1 fails to activate 
the mitogen-activated protein (MAP) kinase or  phosphatidylinositol 3-kinase 
(PI3K)/Akt kinase signaling cascades in NIH3T3 cells, suggesting that Rit1 uses 
novel effector pathways to regulate proliferation, transformation and 
differentiation.15,16 These alternative approaches to inhibition of Rit1 are therefore not 
directly available. 
With a view towards finding small molecule inhibitors of Rit1, we have employed a 
fragment based drug discovery approach.17 Given the large number of GTPases 
present in the cell and the apparent lack of post-translational modification, we sought 
compounds that would specifically bind to and stabilize the Rit1-GDP complex, 
thereby inhibiting Rit1 dependent transcription. Validated screening hits were 
elaborated by analogue searching and synthetic chemistry which generated 
phthalimide based inhibitors exhibiting a modest micromolar affinity as judged by a 
biochemical nucleotide exchange assay.14 Although we were able to elucidate a 2.3 
Å resolution X-ray crystal structure of Rit1 bound to GDP, attempts to soak the 
inhibitors into the Rit1-GDP crystals were fruitless. Therefore, we have used NMR 
based methods to obtain structural information to guide further compound elaboration 
efforts. The resulting docking model suggests that the compound binds adjacent to 
the GDP. The structural information is consistent with the mode of inhibition observed 
in the biochemical assay. 
Results & Discussion  
Crystal Structure of Rit1 bound to GDP 
The crystal structure of Rit1 bound to GDP (Figure 1) to 2.3 Å resolution by 
molecular replacement using the ras-like protein TC21 as a search model (PDB: 




protein exhibited multiple crystal contacts apparently contributing to a rather rigid 
overall structure as judged by the low B-factors.  Not unexpectedly, the structure of 
Rit1 is similar to other small GTPases and consists of the canonical fold comprising a 
β sheet with one anti-parallel and four parallel strands surrounded by four α-
helices.18,19 Electron density was not found for the switch II loop formed by residues 
79-87, likely due to flexibility. Based on structural similarity to other GTPases, the P-
lobe (orange), which forms the characteristic phosphate binding loop, consists of 
residues Leu 27 – Lys 34 in Rit1, while the switch I loop extends from Phe 46 to Ala 
57. The orientation of the GDP nucleotide is conserved and the magnesium ion is 
coordinated by the oxygens of the β phosphate of the nucleotide. The electron 
density for the GDP and magnesium ion was clearly interpretable. Further 
commentary on the structure is provided in the Supplementary Information (Table 
S1). 
Screening for Rit1-GDP Specific Ligands  
A strategy was employed to search for ligands specific for GDP bound Rit1, in 
which. Ligand screening was accomplished using TINS (Target Immobilized NMR 
Screening) on both the apo and GDP bound forms of the protein, screening against a 
fragment collection and hits that were unique for the complex were further 
investigated.20,21 The PH domain of human Akt1 was used as a reference protein. 
Both Rit1 and the Akt1 PH domain were immobilized using Schiff’s base chemistry, 
which at the pH used primarily targets the amino terminus. The functionality of 
immobilized Rit1 was determined using a nucleotide exchange assay 
(Supplementary Figure S1).14 Immobilized GDP-free Rit1 was generated by 
incubation with alkaline phosphatase (AP) in the presence of a non-hydrolysable 




nucleotide free Rit1 rapidly precipitates, ligand screening could only be accomplished 
using an approach such as TINS where the protein is immobilized on a solid 
support.22 
 
Figure 1. The crystal structure of Rit1. The switch I loop is shown in red and the 
phosphate recognition region, also called the P-lobe, in orange. These loops are defined 
based on the structural similarity of Rit1 to other GTPases.18,19 The yellow sphere 
indicates the magnesium ion coordinated by the oxygens of the β phosphate of the 
nucleotide. The electron density for residues that form the switch II loop is missing and 
hence not represented in the crystal structure. The GDP is shown in sticks (green, 
orange, red and blue). 
 
A library of nearly 1,000 commercially available fragments was screened against 
both the GDP-bound and apo-form of Rit1. The design philosophy and characteristics 
of the library have been previously described.23 The hit rate observed was 3.4% and 
8.8% for GDP bound- and Apo-forms of Rit1 respectively, consistent with the idea 






resulted in the identification of 33 and 99 fragments with affinity for the GDP-bound 
and apo-forms of Rit1, respectively. 18 of the fragments bound both forms of Rit1, 
while the remaining hits bind specifically to either apo or GDP-bound Rit1. 
Characterization of primary fragment hits 
All hits from the TINS screen were assayed for inhibition of nucleotide exchange 
using purified protein.14 Rit1 has an intrinsically slow off-rate for GDP and, since no 
GEF specific for Rit1 is known, it is not practical to perform the assay under 
equilibrium conditions.24 Each hit from the screen was assayed at 4 mM and 
subsequently the IC50 of hits that exhibited a percentage of inhibition (PIN) above 
60% was determined where possible. Since it did not prove possible to determine the 
IC50 of all weakly binding fragment hits, the fragments were ranked according to the 
PIN (See supplementary Figure S2). The five fragments, which exhibited a PIN 












Figure 2. The five most potent fragment hits in the nucleotide exchange assay. The 
percentage of inhibition of the nucleotide exchange (PIN) and IC50 values are indicated. 




















Our repeated attempts to either soak 1 into existing crystals of Rit1·GDP or co-
crystallize the ternary complex were unsuccessful. In previous reports a series of 
hydroxylamine bearing inhibitors were shown to inhibit the intrinsic nucleotide 
exchange of Ras.25,26 The NMR based structure of a Ras-inhibitor (SCH-54292) 
complex revealed that the conformation of the rather flexible switch II region may be 
locked by the binding of the inhibitor to this region. The switch II region is known to 
play a role in the rate of nucleotide exchange.25 The naphthyl moiety of SCH-54292 
is buried in a hydrophobic pocket in the vicinity of switch II, while the hydroxylamine 
at the other end of SCH-54292 likely chelates the Mg2+ ion. As seen in the crystal 
structure of Rit1, the presence of the Mg2+ ion is critical for nucleotide binding and is 
co-ordinated by the oxygens of the β phosphate of the GDP. Based on the Ras-
inhibitor (SCH-54292) NMR structure, it was hypothesized that 1 might bind to Rit1 in 
a pocket adjacent to GDP and in the vicinity of the Mg2+ atom. The carboxylic acid 
moiety together with one of the carbonyl groups of the phthalimide ring, was 
hypothesized to chelate the metal. However, with the inability to obtain a crystal 
structure, no conclusive experimental data was available to identify the binding site of 
1. In order to test the binding hypothesis, we sought commercially available 
analogues of 1. Substructure searches were used to first find analogues containing 
additional molecular features on the phenyl ring of 1. A second set of analogues was 
selected to replace the acetate motif on the N of the phthalimide with groups that 
would either ligate the Mg2+ tighter or provide a conformation more optimal for 
ligation. If metal ligation was indeed important for binding, some of these analogues 
would be expected to show improvement in potency in the nucleotide exchange 
assay. Each of the analogues was assayed for inhibition of nucleotide exchange and 




than 1, (~1.5 fold) while compound 7 resulted in a 4 fold increase in the potency. 
However, introduction of a phenyl group at R1 as in compounds 8 and 9, results in a 
roughly six fold improvement in potency compared to 1. The SAR data suggested 
that the carboxylic acid functionality was required at only one end of the molecule 
and that addition of a hydrophobic, preferably aromatic, moiety at the other end could 
lead to enhanced potency, although the ligand efficiency remained rather low (~0.14 
pIC50/Heavy atom count).27 Interestingly, it did not appear to matter which end of the 
molecule contained the carboxylic acid or the aromatic ring. However, the data did 
not give a clear picture of whether or not metal ligation was important for binding. 
 
 
Table 1. Representation of the expansion process from primary fragment hit. The table 
shows the features that were explored by modification of R1 and R2 groups resulting in the 



















































Since crystallography failed to yield structures of Rit1 with any ligand other 
than GDP, we turned to protein observed NMR to obtain structural information. It is 
well known that the 2D [1H,15N]-HSQC NMR experiment can provide low resolution 
structural information on ligand binding if the backbone resonance assignment of the 
protein is available. Using standard through-bond, triple resonance NMR 
experiments, the sequential assignment for about 72% of the backbone of Rit1 was 
determined (see Experimental Section). Subsequently, compound 8 was titrated into 
uniformly 15N labeled Rit1 and residues with significant chemical shift perturbations 
(CSP) of the amide cross peak were identified (δH > 0.01 ppm). Potential binding 
sites were mapped onto the Rit1 crystal structure using the program j-surf.28 Note 
that the NMR titration experiments were carried out at pH 9.1 as the stability of the 
protein was significantly greater than at pH 7.5, the pH at which the TINS screen was 
performed. Significant CSPs were clearly observed close to the the GDP binding site 
and on the opposite side of the protein close to the diphosphate moiety (Figure 3). 
Although this data gave us confidence that the ligand bound close to the nucleotide, 





Figure 3. Mapping of the chemical shift perturbations induced by binding of 8 onto Rit1. The  
program j-surf was used to calculate potential binding sites.28 The small dots forming spheres 
indicate the likely binding site of the compound as determined by j-surf. The red and orange 
colors represent the location and magnitude (larger and smaller respectively) of significant 
chemical shift perturbations observed on the protein. A and B show the two possible binding 













Scheme 1. Synthetic approach to elaborate compounds based 8. Three different series of 
compounds 16a-e, 17a-e and 18a-c (see Table 1) were accessible via this scheme. See 
experimental section for more information. Reagents and conditions; i) AcOH, MW 165°C, 
5h. ii) EtOH, Pd/C, 2h. iii) BnCl, KOH, H2O, reflux, 16h. 
 
Elaboration of Compound 8 
The chemical shift binding data, while not precisely defining the mode of 
interaction of 8 with Rit1, did suggest the presence of a shallow, hydrophobic patch 
adjacent to one of the binding sites. Based on this model, we explored the SAR 
around 8 using the approach outlined in scheme 1. For optimization of compound 8, 
we focused on modifications of the phenyl (R1-) and acidic (R2-) ends of the 
molecule, keeping the carbon functionalized phthalimide ring structure intact. 
Replacement of the phenylethyl group with either a benzyl-oxy or a phenyl-ethynyl 
moiety resulted in compounds (16a-d and 17a-d) with no significant gain in potency 
(Table 2). The linker to the carboxylic group was modified to include a second 
methylene carbon to give compounds 16b and 17b with 2-methyl – acetic acid 
functionalized carbon phthalimides, however extension of the linker did not result in 
improved potency. The linker was then modified to include a branched methyl group 
with either (S) or (R) stereochemistry (16c-d,17c-d and 18a-b). All analogs 
containing the S stereoisomer led to reduced or unchanged potency. However, the R 













































enantiomer, except in the case where the phenyl ring is connected via an ethyne 
spacer to the phthalimide core. In this latter case the reduced flexibility may affect the 
interaction of the acidic end of the molecule with the protein. A further significant 
improvement in potency (about 4 fold) was achieved by addition of a phenyl ring to 
the branched (R) methyl group resulting in compounds 16e, 17e and 18c. As 18c 
was found to be the most soluble of this series, it was pursued for biophysical 
characterization.30,31,32 
Determining the binding site of compound 18c 
 
 Compound 18c was titrated into 15N labeled Rit1 and the chemical shift 
perturbations in the [1H,15N] HSQC experiment were again mapped onto the crystal 
structure (PDB 4KLZ).33,34 The key protein residues involved in binding are Tyr 167, 
Tyr 169, Tyr 170 and Asp 137, which are adjacent to the GDP binding pocket. In 
addition to these residues, CSPs were also observed for residues 107, 110, 116, 
113, 90 and 94, similar to what was observed for compound 8, indicative of a 
secondary binding site. However, it is to be noted that this secondary site is close to 
the switch II loop of Rit1 that is missing from the crystal structure. This might suggest 
that these CSPs could be either due to a conformational rearrangement caused upon 
binding of 18c or influenced by the flexibility of this part of the protein. As the data 
suggests the possibility of two binding sites, further structure restraints were 
necessary in order to more precisely define the nature of the binding of 18c to the 
protein and to shed light on the mechanism of inhibition of nucleotide exchange. 
Since sidechain resonance assignments were not readily available due to the 
marginal quality of the NMR spectra, we chose to investigate the use of 
paramagnetic NMR effects for structure elucidation by introducing an organic radical 






















































































































































The presence of the unpaired electron of MTSL results in Paramagnetic 
Relaxation Enhancement (PRE) of affected NMR resonances. The PRE effect is 
dependent (r-6) on the distance between the nucleus and the unpaired electron and 
can be readily calibrated by observing the effect on resonances of the protein. 
Determination of the PRE effects thus provides unique, long range distance 
information, typically from 12 to 22 Å.35 In order to calibrate the PRE effects, a 2D 
[1H,15N] HSQC spectrum was recorded of 15N labeled Rit1 with either the 
paramagnetic GDP-SL or diamagnetic GDP bound. For each observed amide 
proton, the intensity ratio (Ipara/Idia) of the resonances in the paramagnetic and 
diamagnetic spectra was determined, from which the PRE was converted into a 
distance as described.35 The observed distances were then used to back calculate 
the position of the radical using the Rit1-GDP crystal structure. The average 
position of the nitroxide radical of the GDP-SL relative to the protein backbone 
could be determined with high reliability and was found to be close to the bound 
GDP in the crystal structure. The back-calculated nitroxide to amide proton 
distances match the experimentally determined distances very well, as judged by 
the low Q-value of 0.059  (Supplementary Figure S3). Q value is a statistical 
parameter in which the distances from the docking model are compared to the 
experimentally obtained. The smaller the value, the better the fit of back calculated 
versus experimental data. A model of the nitroxide spin labeled GDP bound to Rit1 
was generated based on the experimental distances using XPLOR-NIH (For more 
details refer to the experimental section).36 The model was subsequently used to 
characterize the binding of 18c. 
The PRE effect on the 1H resonances of 18c was determined by comparing the 




Figure 4, resonances of 18c are broadened in the presence of diamagnetic 
Rit1·GDP, confirming that it binds to the binary complex. Most, but not all, of the 1H 
resonances of 18c are further broadened beyond detection in the presence of 
paramagnetic Rit1·GDP-SL, indicating that they are strongly affected by the presence 
of the spin label. The observed PRE’s were converted into distances as was done for 
the protein, taking into account the fractional occupancy. These intermolecular 
distance restraints were then used to calculate a model of the ternary complex of 
Rit1·GDP-SL·18c by docking. 
 
Molecular Docking using PRE distance restraints 
All observable protons of 18c experience a paramagnetic effect of varying 
degrees due to the nitroxide radical of the GDP-SL, indicating that all protons from 
the compound must approach the GDP-SL for at least some part of the time (Figure 
4). The docking calculations were performed using the PRE restraints, CSPs and 
saturation transfer effects. Saturation transfer measurements (STD) were performed 
to obtain structural information on the spatial proximity of ligand protons to the protein 
surface. This approach, also known as group epitope mapping, was originally 
proposed by Mayer and Meyer, 2001.37,38,39 In the case of 18c, the saturation transfer 
curves show similar kinetics for all protons suggesting that either the ligand binds in 
different orientations or is approximately equally surrounded by the protein on all 
sides. As a result, the STD data was included as ambiguous restraints in the docking 
procedure (Figure S6). The resulting structures exhibited a poor correlation between 
experimental restraints and back calculated distances with a Q-value of 0.07 (Figure 
S7). Specifically, the average distances in the ensemble of docked structures is 





Figure 4. Paramagnetic relaxation enhancement (PRE) effect on the 1H resonances of 
18c bound to Rit1·GDP-SL. The structure of compound 18c is indicated with proton 
assignments. The corresponding resonances in the aromatic portion of the 1H NMR 
spectrum are indicated. A reference spectrum of 18c is provided (red). Peak broadening in 
the presence of Rit1·GDP (green) is indicative of binding. Further broadening due to PREs is 
clearly observed for many resonances in the presence of Rit1·GDP-SL (blue). A reference 
spectrum of Rit1 ·GDP-SL in the absence of 18c is provided (brown). Due to considerable 
overlap in the resonances caused by the overall symmetry of 18c, one proton (3) could not 
be definitively assigned and resonances arising from protons 8 and 1 could not be 
distinguished. The resonances from the aliphatic region of the 1D spectrum are shown in the 
SI (Figure S5). 
 
 The pattern of violations observed in the docking based on a single set of 
restraints suggests the possibility of averaging over multiple orientations or possibly 
binding sites. Given the symmetry of the compound, with the two phenyl groups 
attached to the phthalimide moiety, it is conceivable that the compound binds in two 
orientations. Therefore, it was decided that the PRE-based distance restraints should 
          
  




















be divided into two groups, i) one PRE set representing the protons of the acidic side 
of the compound and ii) a second PRE set representing the protons of the non-acidic 
side of the compound. Subsequent docking calculations were performed with either 
of the two sets of PRE restraints, CSPs and the ambiguous restraints from STD. The 
five lowest energy solutions from each of the two calculations show two minima 
(Figure 5). In one binding mode, defined by the restraints from the non-acidic end, 
18c lies in a shallow groove parallel to the sugar and phosphates of GDP and 
crosses over to occlude the base. In the second binding mode, the compound binds 
in the groove above the β3-strand formed by residues 160:163. Within the five lowest 
energy structures for each of the binding modes, 18c is found in two orientations, 
rotated by approximately 180 degrees. In contrast to the calculations in which all of 
the PRE restraints were simultaneously used, the intermolecular distance restraints 
for the two ensembles of five structures fit very well to the experimentally determined 
distances, with a Q-value of 0.04 (supplementary Figure S7). 
Discussion and Conclusion 
In this work we aimed to develop small molecule inhibitors of the small 
GTPase Rit1, a novel target for rheumatoid arthritis.2 We report here for the first time 
the crystal structure of Rit1 bound to GDP solved to 2.3 Å. This was a useful starting 
point, but since it proved impossible to obtain structures with the inhibitors bound did 
not directly aid in driving design. Thus, the elaboration of the initial 3 mM fragment hit 
was based on structural information obtained by NMR methods. The NMR methods 
were selected for the ability to rapidly generate reliable constraints for molecular 
docking studies and included chemical shift perturbations derived from 2D [1H,15N] 
HSQC spectra, epitope mapping by saturation transfer difference spectroscopy and 


















two types of restraints can also be employed in cases where isotope labeling of the 
target is not possible. This demonstrates that NMR can provide structural information 
with sufficient detail and timeliness to support medicinal chemistry efforts when X-ray 
crystallography is not available. Although the directly modulation of GTPase activity 
with small molecules has proven challenging, we have been moderately successful in 
elaborating the phthalimide based inhibitors to an IC50 of approximately 180 µM. 
Importantly, the inhibitors have a novel mode of action. 
 
Figure 5. Experimentally restrained docking of 18c onto the Rit1·GDP-SL complex. A] The 
lowest energy binding solutions as determined by docking using restraints from PRE, CSP 
and saturation transfer. The surface of Rit1 is presented and the bound GDP-SL (green) is 
shown in bond representation. The presence of magnesium ion is indicated by a red sphere. 
Compound 18c is also shown in bond representation (narrow lines) where the two different 
orientations, rotated by 180°, are shown in red and blue. Amino acids with significant 
chemical shift perturbations observed in the presence of compound are shown in orange. 
The protein residues for which there are no assignments available are shown in pale green. 
B] Closeup view of one of the binding modes of compound 18c binding adjacent to the GDP-





The Rit1·GDP·18c complex  
The PRE based data and the subsequent docking results reveal that 
compound 18c does not bind Rit1 in one preferred orientation or even within a single 
binding site. Rather, 18c explores a large surface near the GDP binding pocket of 
Rit1. The two specific binding modes found in the restrained docking indicate that 
18c binds in a shallow groove. These two binding grooves are physically separated 
in the Rit1 crystal structure by the bulk of the loops consisting of residues 135 - 145 
and 165 – 170, although at the closest points the two sites are within 6.5 Å and 
translocation from one site to the other could be accomplished by a simple flip 
(Figure 5). Interestingly, the Hill slope of 1.6, which suggests somewhat greater than 
1:1 stoichiometry, is consistent with the two binding modes from the docking. In 
Figure 4, it is clear that protons from both phenyl rings of 18c, which are some 12 Å 
distant, experience a considerable paramagnetic effect. This data means that both 
phenyl rings of 18c must closely approach the MTSL during the complex formation, 
at least for some part of the time. For the base occluded binding mode, both ends of 
18c are sufficiently close to MTSL that in principle a single orientation could explain 
the data, however, two orientations are found in the docking ensemble. For the 
binding mode close to the β3-strand, 18c must bind in both orientations (i.e. flipped 
180 degrees) in order to satisfy the data. As the complex is in rapid exchange on the 
NMR timescale, it seems likely that the two orientations are exchanging rapidly as 
well and indeed, there may be additional rapid exchange between the two binding 
modes.  To our knowledge, this is the first documented case of a small molecule 
exchanging between multiple binding poses, although this behavior is frequently 
invoked in fragment based drug discovery as a possible explanation for the failure to 
observe ligands in crystal structures of the target.  




groove and in particular, the base occluded binding mode is unusual. In principal the 
addition of the organic radical at the 2’ carbon of the sugar of GDP could perturb the 
structure of Rit1 and create an artificial binding site. For the β3-strand binding site, 
this seems particularly unlikely since the site is remote from the sugar and there is no 
evidence from the PRE data that the crystal structure is perturbed in this region. On 
the other hand, the base occluded site is adjacent to the GDP and could possibly be 
influenced by the presence of the MTSL. However, three observations argue against 
this possibility. First, the MTSL is on the other side of the GDP and does indeed 
perturb the structure of Rit1, but in a flexible loop distal to the proposed binding site 
of 18c (Figure S4). Second, there are extensive CSPs induced by the binding of 18c 
to the native Rit1:GDP complex in the base occluded binding site. This suggests that 
18c binds at this site even when the MTSL is absent. Thirdly, a truncated-driven NOE 
experiment suggested that the aromatic protons of a closely related compound were 
within 5Å of the imino proton of the base (data not shown).40 The base occluded 
binding mode is most consistent with this data, even though no restraints based on 
the data were included in the calculation. In the base occluded model, the Mg2+ ion is 
on the opposite side of the phosphates of GDP from 18c, therefore, it seems unlikely 
that the compound binds via metal chelation. 
Novel mode of nucleotide inhibition 
 Recently the crystal structure of an “inactive” form of GTP bound HRas 
has been elucidated.41 In this structure the Switch I loop is significantly displaced 
from the nucleotide, theoretically creating a potential small molecule binding site. 
One could speculate that if a similar Switch I displacement occurred in the GDP 
bound state a similar binding site might exist. However, if it does, it is on the opposite 




any data to suggest that 18c nor any of the other compounds in this study might bind 
at such a hypothetical site.  A small molecule binding site with allosteric properties 
has been found on KRas.42 Interestingly, small molecules bind this site in the 
presence of either GDP or GTP analogues. Apparently, binding at this site inhibits 
the interaction with the GEF SOS. This allosteric site however is remote from the 
base occluded binding site (Figure 6), suggesting that 18c acts with a novel 
mechanism, that is steric inhibition of GDP release. This new binding site may point 
towards a new approach to inhibit this pharmaceutically important yet challenging 
class of targets.   
 
Figure 6. The comparison of the docked model of Rit1·GDP·18c complex with 
KRasm·GCP:small molecule complex. The docked model of the ternary complex, Rit1·GDP-
SL·18c (orange) is shown overlaid with and the structure of KRasm·GCP:small molecule 
complex (blue, PDB:4DST). The two binding sites for 18c are shown in orange and dark pink 
color. It is seen that 18c binding sites are distal from the pocket 1 and switch II region but lie 
close to pocket 2. The allosteric binding site found for small molecule bound to KRasm lies 















For X-ray crystallography, an N-terminal cleavable hexahistidine tagged-Rit1 
construct (aa 19-189) was cloned into pQTEV vector and expressed in E. coli BL21 
(DE3) codon plus (RP) (Stratagene). The protein was purified on Ni-Hitrap FF (GE 
lifescience) followed by purification on a superdex G75 gel filtration column (GE 
lifescience). The hexahistidine tag was removed by the proteolytic digestion with TEV 
protease (Invitrogen) according to the manufacturer recommended buffer condition. 
The cleaved tag and the TEV protease were removed by affinity purification on Ni-
Hitrap FF, and subsequently the buffer of Rit1 (19-189) was exchanged to 20 mM 
Tris pH9, 5 mM NaCl, 2 mM MgCl2 and 1 mM DTT.   
For NMR studies, a C-terminal hexahistidine tagged-Rit1 (aa 19-189) was 
cloned into pET20b and expressed in E. coli strain BL21 (DE3) Codon Plus (RP) 
(Stratagene). The protein was first purified on Ni-Hitrap FF (GE lifescience) followed 
by purification on Superdex G75 with  buffer of 20 mM Tris pH 9, 5 mM NaCl, 2 mM 
MgCl2 and 1 mM DTT. To obtain sequential backbone resonance assignments, 
uniform 13C, 15N labeling of Rit1 was achieved by expression of C-terminally 
hexahistidine tagged Rit1 (aa 19-189) in BL21 (DE3) Codon Plus (RP) cells grown in 
M9 minimal medium supplemented with 15NH4Cl and 13C-D-Glucose (CIL) as sole 
nitrogen and carbon sources. The protein was purified as described above. For 
protein observed HSQC studies, 15N labeled C-terminal hexahistidine tagged Rit1 (aa 
19-189) was produced in M9 minimal medium supplemented with 15NH4Cl as a sole 
nitrogen source and purified as described above. 
For nucleotide exchange assay, a N-terminal GST (Glutathione S-transferase) 





Crystallization and structure determination of the Rit1·GDP complex 
The protein was concentrated to 10 mg/mL concentration prior to 
crystallization.  The Rit1 crystals were grown in the presence of 11-14% w/v PEG 
4000, 5-8% v/v Jeffamine M600 and immidazole buffer pH 7.0-7.2 using sitting drop 
vapour diffusion method.  The crystals were harvested with a nylon loop and 
transferred to cryo-conditions by briefly passing the crystals through mother liquor 
augmented with approximately 30% glycerol. The crystals were then flash-frozen by 
exposing them to the cold-stream of the X-ray source. All the diffraction data was 
collected using a Cu-Kα rotating anode X-ray generator and a CCD area detector. 
The best diffracting crystals grew on the plastic surface of the crystallization well and 
diffracted up to 2.3 Å on a rotating anode X-ray beam. The diffraction data were 
integrated and scaled with the PROTEUMplus Crystallographic Software Suite by 
Bruker AXS and processed by CCP4 (Collaborative Computational Project, Number 
4. 1994).44 The structure of the protein was solved by Molecular Replacement, using 
the ras-like protein TC21 (PDB: 2ERY); 55% sequence identity) as a search model. 
Molecular replacement was carried out with the MOLREP routine in CCP4 by 
searching for one molecule in the asymmetric unit. The refinement of the MR solution 
was carried out using REFMAC5 from CCP4. Model building for the structure of Rit1 
was carried out with the program COOT. 44,45. The co-crystallization and soaking trial 
experiments for protein compound complex were unsuccessful and caused protein 
crystals to crack.  
 
TINS NMR screening 
Rit1 (aa 19-189) and Akt PH domain (aa 1-123) were immobilized via amine-




NaCl and 2 mM MgCl2 at 4°C using the coupling reagent provided by the 
manufacturer.  Due to low solubility of Rit1 at pH 7.5, the protein was immobilized in 
consecutive addition at 50 µM. The immobilization efficiency was above 90% and the 
final concentrations of the immobilized targets were typically in the range of 500 µM. 
The immobilized Rit1 was shown functional by the nucleotide exchange activity 
(Shao, H, et al 2000).14,43 TINS NMR experiments were performed on 500 MHz 
Bruker NMR spectrometer using spatially selective Hadamard pulse sequences and 
analyzed as described previously.20,46,47 GDP-bound Rit1 was immobilized as 
described above. The composition of the fragment library screened has been 
reported previously.23 The typical fragment mix applied to the immobilized proteins 
consisted of 3 ~ 5 fragments which were each at 500 µM. The buffer used in the 
screen was comprised of 25 mM Tris-d11 pH 7.5, 100 mM NaCl, 1 mM MgCl2 for 
GDP-bound from of Rit1. 
 
In vitro nucleotide exchange assay / High concentration bioassay 
The nucleotide exchange was determined by the rapid filtration technique. The 
exchange buffer comprised of 1 µM of GST-Rit1 (aa 1-201), 2 µM [32S] GTPγS (2 
Ci/mmol, PerkinElmer) in 25 mM Tris pH 7.5, 100 mM NaCl, 1 mM DTT and 0.5 mM 
MgCl2 (on ice), and then the spontaneous nucleotide exchange was initiated by 
incubation at 30°C. After 1 hour incubation at 30°C, the [32S] GTPγS bound GST 
fusion protein was isolated onto 96-well Unifilter GF/B using Filteramate harvester 
(PerkinElmer) with cold wash buffer of 25 mM Tris pH 7.5, 100 mM NaCl, 1 mM DTT 
and 10 mM MgCl2. The filter was soaked in Microsint scintillation fluid and the bound 
[32S] GTPγS was detected using TopCount (PerkinElmer). All the fragments 




concentration bioassay. Initially, the total nucleotide exchange was monitored in the 
presence of fragment or in DMSO. The amount of DMSO in the controls was 
matched to 1.5% (v/v), which is equivalent to the amount in the presence of a 
fragment. In 96 wells, 8 wells containing either DMSO or 400 µM of GDP were 
employed as internal controls. The percentage of inhibition (PIN) was determined as 
follows: PIN (%) = [1 - (A fragment – A positive control) / (Anegative control – Apositive control)] x 
100%, where A fragment and Anegative control are the radioactive counts measured in the 
presence of fragments and DMSO, respectively, whereas Apositive control is the 
radioactivity measured in the presence of 400 µM of GDP that competed out [35S] 
GTPγS for the nucleotide site in Rit1. The diagrammatic representation of the 
nucleotide exchange assay is shown in Figure S10. 
 
NMR backbone sequential assignment 
The following NMR experiments were acquired at 293K on an 800 MHz Varian 
Inova spectrometer; [1H,15N] -HSQC, HNCO, HNCA, HNCACB, CBCACONH and 3D 
[1H,15N] NOESY-HSQC.33,34 The protein sample consisted of 0.5 mM Rit1 (aa 19-
189) in 25 mM d11-Tris pH9, 5 mM NaCl and 5 mM MgCl2. The data was processed 
using NMRPipe and visualized using Sparky.48,49 The assignment process was 
guided by the automatic assignment program MARS using PDB 4KLZ  as an input.50 
 
Chemical shift perturbation and generation of binding site 
The [1H, 15N]-HSQC were acquired at 298K on 600 MHz Bruker DMX NMR 
spectrometer equipped with a TXI cryo-probe.33,34 The NMR sample was prepared in 
25 mM Tris pH 9, 5 mM NaCl and 5 mM MgCl2. The typical NMR sample contained 




DMSO. The pH of the samples was adjusted carefully within +/- 0.05 units after 
addition of the compound. During the experiment, total of 128 indirect increments 
with 16 scans per increments were acquired. The data was processed using Topspin 
1.2/2.1 (Bruker) and visualized on Sparky.49 Chemical shift perturbation in [1H, 15N]-
HSQC was calculated for change in 1H ppm value between in the presence and 
absence of a compound. The potential binding sites of a compound were mapped 
onto the surface of the Rit1 structure by jsurf using chemical shift perturbation data 
(delta 1H ppm) as input.28 
 
Saturation Transfer Experiments 
Saturation transfer NMR experiments were conducted using pulse sequences 
as described.37,38,39 The protein concentration was 40 µM and compound was 
present at a 20 fold in molar ratio. The pH of the sample was adjusted carefully within 
+/- 0.05 units. The on-resonance irradiation of the protein was performed at -0.5 ppm 
and off-resonance irradiation was performed at 100 ppm where no protein signals are 
present. The saturation time was varied between 50 ms to 2 sec in order to 
determine the buildup rate. No significant differences in the buildup rate between the 
protons were observed (see supplementary figure S6). 
 
Paramagnetic NMR Studies  
Synthesis of GDP-Spin label   
The procedure followed was modified from literature.51,52,53 One equivalent 
each of 3-Carboxy-2,2,5,5-tetramethyl-3-pyrrolin-1-yloxy, Free Radical (Toronto 
Research Chemicals) and N,N-carbonyldiimizdazole (dissolved in dimethyl 




guanosine diphosphate sodium salt (Sigma) was added and incubated further for 1 
hour at 38°C water bath while stirring and pH adjusted to 9.1 using 1 M NaOH. The 
reaction mixture was extracted twice with chloroform and pH of the aqueous phase 
was adjusted to pH 7.5 with 1N acetic acid. The solution was filtered and was further 
subjected to LCMS analysis using reversed-phase HPLC purification using an 
automated HPLC system supplied with a semi-preparative C18 column (10.0 mmD × 
250 mmL, 5 µ particle size) was used. Mass spectra were recorded for elutes and 
yielded the product of expected size. Purified elutes were further lyophilized and 
gave a typical pale yellow color, characteristic of the presence of nitroxide radical. 
The presence of radical was further confirmed by acquiring an EPR spectrum. The X-
band cw EPR measurements were performed using an ELEXSYS E680 
spectrometer (Bruker, Rheinstetten, Germany) equipped with a rectangular cavity. A 
modulation frequency of 100 kHz was used. Measurements were done at 
temperature of 20°C, using 6.31 mW of microwave power and modulation amplitude 
of 0.5 G (See Figure S8 in supplementary). 
 
PRE studies on Protein  
The removal of GDP was performed by buffer exchange into 20 mM HEPES 
pH 7.5, 1 mM EDTA, 1 M (NH4)2SO4, 20 % glycerol.54 The GDP removal was 
checked by disappearance of a peak at 260 nm in the UV absorption spectrum. The 
ability of apo-Rit1 to bind to chemically modified GDP was checked by a fluorescent 
based- assay. In this assay, MANT-GDP [(2'-(or-3')-O-(N-methylanthraniloyl) 
guanosine 5'-diphosphate] (Biolog, Germany) was titrated into apo-Rit1 and change 
in the intensity of the MANT fluorescence caused by binding to Rit1 was measured in 




a 1:1 stoichiometry to apo-Rit1. As MANT-GDP carries a similar chemical 
modification at the ribose moiety of GDP as in the GDP-SL, we assumed that this 
would lead only to a minimal perturbation of Rit1-GDP-SL interaction (data not 
shown). The protein was exchanged back into the buffer composed of 25 mM Tris pH 
9, 5 mM NaCl and 5 mM MgCl2.  The paramagnetic GDP-SL was added at a 1.5 
molar excess over protein,  incubated on ice for 30 min and then washed three times 
with  25 mM Tris pH 9, 5 mM NaCl and 5 mM MgCl2 using a Centricon centrifugal 
concentrator with MWCO 10 kDa (Millipore). The same procedure was followed 
during preparation of diamagnetic control sample except that diamagnetic GDP 
(SIGMA) was added. The protein concentrations used were identical during NMR 
measurements. NMR samples contained, a paramagnetic sample consisting of 0.1 
mM Rit1 bound to GDP-SL and a diamagnetic control consisting of 0.1 mM Rit1 
bound to GDP in 25 mM Tris pH 9, 5 mM NaCl and 5 mM MgCl2, 5%D2O. The 
measurements were performed at 298 K on 600 MHz Bruker DMX NMR 
spectrometer equipped with a TXI cryo-probe. During the experiment, total of 128 
indirect increments with 16 scans per increments were acquired. The data was 
processed using Topspin 2.1 (Bruker) and visualized using Sparky.49 
 
PRE studies on compound 18c   
C-terminally hexahistidine tagged Rit1 (aa 19-189) was expressed and purified 
as described above. The paramagnetic and diamagnetic protein samples were made 
as described above. The compound was added to the protein sample at a ratio of 
1:1. 1D proton NMR spectra were acquired at 298 K on 600 MHz Bruker DMX NMR 
spectrometer equipped with a TXI cryo-probe.  A CPMG delay of 40 ms was used to 




(Bruker). For each observed amide proton, the intensity ratio (Ipara/Idia) of the 
resonances in the paramagnetic and diamagnetic spectra was determined, from 
which the PRE was converted into a distance as described.35 The minor variations in 
the intensities for the compound signals in the 1D spectrum diamagnetic and 
paramagnetic sample of 18c in the presence of the protein were referenced to the 
signal from DMSO.  
 
Docking of Rit1·GDP·18c ternary complex  
PREs of amide protons of the protein were obtained from peak intensities in 
HSQC spectra of paramagnetic and diamagnetic protein and subsequently used to 
determine the position of the nitroxide radical relative to the protein crystal structure. 
For this, the interatomic proton to radical distances were determined from the PREs 
as described,35,55 using an experimentally determined correlation time of 11.5 ns. The 
correlation time was determined using [1H,15N] HSQC analysis with varying T1 and 
T2 delays The distances were divided into three different classes. The protons for 
which the resonances were broadened beyond detection, were given an upper limit 
of 14 + 3/-8 Å, protons of which the resonances were unaffected, were given a lower 
limit of 21 + 100/-3 Å. The distances for 27 protons, lower limits for 25 and upper 
limits for 5 protons were used to obtain the energy minimum of the nitroxide radical 
using XPLOR-NIH.36 
The compound was docked onto the GDP-SL·Rit1 complex using XPLOR-NIH 
using experimental restraints from the CSPs data by HSQC NMR titration (some 
CSPs are shown in Figure S9), saturation transfer and paramagnetic experiments.36 
Based on the measured PREs, 10 distances between 1Hs of 18c including two 




determined by titrating the compound into the protein as determined by HSQC, were 
translated into ambiguous distance restraints of 6 +/- 3 Å to any compound proton 
while averaging over <r-6>. Similarly, based on the saturation transfer experiments, 
ambiguous distance restraints of 5 + 4/-3 Å were applied between any compound 
proton and any protein carbon atom. Protons were subsequently added manually. In 
a typical simulation, the compound approached the protein 10,000 times, where the 
compound was placed at a random position every four approaches the energy did 
not drop. The compound was treated flexible and was initially docked on the 
backbone of the protein including Cα and Cβ followed by inclusion and optimization 
of the sidechains. (The docking script is provided in the Supplementary Information; 
S12). The docking results are evaluated by a Q-value.35 In this statistical parameter 
distances from the docking model are compared to the experimentally obtained. The 
smaller the value, the better the fit of back calculated versus experimental data. 
 
Model Structure of GDP-Spin Label 
A structure of 3-carboxy-2,2,5,5-tetramethyl-3-pyrrolin-1-yloxy was prepared in 
Spartan (www.wavefun.com) and parameterized using the Prodrugserver.56 The 
chemical structure of the GDP spinlabel probe is shown is Figure S11. Additional 
dihedral and angle parameters were added to keep the nitroxide in plain with the 
pyrroline ring. The molecule was added to the protein and attached to the GDP using 
XPLOR-NIH. To this end, an ester linkage was created between the carboxylate and 
the 2'- hydroxyl of the GDP and the nitroxide oxygen atom was moved in the 
direction of the predetermined minimum energy position. The spin-labeled GDP was 
energy minimized, before optimizing the loop consisting of residues 42:57, 




(Supplementary Figure S4). 
 
Synthesis of elaborative compounds based on compound 8: 
Carbon functionalized phthalimides are synthesized analogues to the literature 
procedure (Scheme 1).i Commercially available 4-phenylenthynylphthalic anhydride 
10 is condensed with the appropriate amino acid in acetic acid under microwave 
irradiation at 165°C for four to five hours yielding the desired products in yields 
ranging from 80% to 97% after recrystallization or HPLC purification. Hydrogenation 
of the triple bond using palladium on charcoal afforded saturated phthalimides similar 
to 12 in yields ranging from 74% to 99% after HPLC purification. Oxygen 
functionalized phthalimides such as 15 were synthesized from 4-benzyloxyphthalic 
acidii (14) in yields ranging from 43% to 78%.30,31  
General: PE with a boiling range of 40 - 60°C was used. THF and Et2O were 
distilled over LiAlH4 prior to use. DCM (dichloromethane) was distilled over CaH2 
prior to use. All other solvents used under anhydrous conditions were stored over 
molecular sieves (4Å) except for methanol which was stored over 3Å molecular 
sieves. Solvents used for work-up and column chromatography were of technical 
grade and distilled before use. Microwave assisted reaction were carried out in an 
Emrys Optimizer (Biotage AB, formerly Personal Chemistry). Wattage was adjusted 
automatically so as to maintain the desired temperature. Unless stated otherwise, 
solvents were removed by rotary evaporation under reduced pressure at 40°C. 
Reactions were monitored by TLC-analysis using DC-fertigfolien (Schleicher & 
Schuell, F1500, LS254) with detection by spraying with 20% H2SO4 in EtOH, 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid 




by charring at ~150°C. Column chromatography was performed on Fluka silicagel 
(0.04 – 0.063 mm). For LC/MS analysis, an JASCO HPLC-system (detection 
simultaneously at 214 and 254 nm) equipped with an analytical C18 column (4.6 mmD 
× 250 mmL, 5µ particle size) in combination with buffers A: H2O, B: MeCN and C: 
0.5% aq. TFA and coupled to a mass instrument with a custom-made Electronspray 
Interface (ESI) was used. For reversed-phase HPLC purification of the final 
compounds, an automated HPLC system supplied with a semi-preparative C18 
column (10.0 mmD × 250 mmL, 5 µ particle size) was used. The applied buffers were 
A: H2O, B: MeCN and C: 1.0% aq. TFA. High resolution mass spectra were recorded by 
direct injection (2 µL of a 2 µM solution in water/acetonitrile; 50/50; v/v and 0.1% formic acid) 
on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion 
source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 
250°C) with resolution R = 60000 at m/z 400 (mass range m/z = 150-2000) and 
dioctylpthalate (m/z = 391.28428) as a “lock mass”.[iii] The high resolution mass spectrometer 
was calibrated prior to measurements with a calibration mixture (Thermo Finnigan). 1H- en 
13C-NMR spectra were measured on a Joel JNM-FX-200 (200/50 MHz). Chemical 
shifts are given in ppm (δ) relative to TMS (0 ppm) or MeOD (3.30 ppm) and coupling 
constants are given in Hz.32,57,58  
General condensation procedure: Phthalic acid or anhydride and the 
appropriate amino acid (1.05 equiv) are suspended in acetic acid (5 mL) and the 
reaction mixture is heated in a sealed tube for five hours at 165°C in the microwave. 
The reaction mixture is concentrated and purified by HPLC or by means of 
recrystalization.57,58,59 
General hydrogenation procedure: The appropriate alkyne is dissolved in 
ethanol (2 ml) and treated with Pd/C (10 mg) and hydrogen gas for 2 hours at r.t. 




concentrated and the residue is, if required, purified by HPLC. 
 
17a: Prepared from 10 (1.24 g, 5 mmol) and glycine (394 mg, 5.25 
mmol) according to the general condensation procedure and 
purified by recrystallization from hot water. Yield: 1.48 g, 4.85 mmol, 97% off white 
solid. 1H NMR (400 MHz, DMSO) δ 13.18 (bs, 1H, CO2H), 8.05 (s, 1H), 8.01 (dd, J = 
1.3, 7.7, 1H), 7.96 (d, J = 7.7, 1H), 7.67 – 7.60 (m, 2H), 7.50 – 7.43 (m, 3H), 4.33 (s, 
2H). 13C NMR (101 MHz, DMSO) δ 168.74, 166.52, 166.43, 137.34, 131.99, 131.71, 
130.53, 129.60, 128.84, 128.60, 125.77, 123.78, 121.36, 93.51, 87.88, 39.02. LC-
MS: tR: 7.91 min (linear gradient 10-90% in 13.5 min), m/z = 611.1 [2M+H]+, 306.1 
[M+H]+, 259.9 [M-CO2+H]+ 
14: Prepared according to literature procedure. Yield: 5.66 g, 20.8 
mmol, 76%. 1H NMR (400 MHz, MeOD) δ 7.94 (d, J = 8.5, 1H), 7.49 – 
7.26 (m, 6H), 7.13 (d, J = 8.6, 1H), 5.15 (s, 2H). 13C NMR (101 MHz, MeOD) δ 
172.33, 170.53, 162.56, 138.18, 137.83, 133.95, 129.86, 129.58, 129.12, 128.68, 
124.84, 117.32, 116.89, 71.30. 
17b: Prepared from 10 (496 mg, 2 mmol) and β-alanine (187 mg, 
2.1 mmol) according to the general condensation procedure and 
recrystallized from EtOAc/PE. Yield: 549 mg, 1.7 mmol, 85% as white solid.  1H NMR 
(400 MHz, DMSO) δ 12.38 (bs, 1H), 7.99 – 7.94 (m, 2H), 7.89 (d, J = 7.6, 1H), 7.65 – 
7.60 (m, 2H), 7.49 – 7.44 (m, 3H), 3.80 (t, J = 7.4, 2H), 2.62 (t, J = 7.4, 2H). 13C NMR 
(101 MHz, DMSO) δ 172.04, 166.92, 166.83, 136.96, 132.24, 131.68, 130.86, 
129.55, 128.83, 128.14, 125.37, 123.39, 121.39, 93.20, 87.95, 33.72, 32.25. LC-MS: 
tR: 7.91 min (linear gradient 10-90% in 13.5 min), m/z = 319.9 [M+H]+, 302.1 [M-



















17c: Prepared from 10 (496 mg, 2 mmol) and alanine  (187 mg, 
2.1 mmol) according to the general condensation procedure and 
purified by recrystallization from hot water yielding the title compound as white solid 
(522 mg, 1.6 mmol, 81%).1H NMR (400 MHz, DMSO) δ 13.14 (s, 1H), 8.05 – 7.99 
(m, 2H), 7.94 (dd, J = 0.6, 7.7, 1H), 7.67 – 7.61 (m, 2H), 7.50 – 7.45 (m, 3H), 4.89 (q, 
J = 7.3, 2H), 1.56 (d, J = 7.3, 3H). 13C NMR (101 MHz, DMSO) δ 170.89, 166.45, 
166.35, 137.31, 131.89, 131.71, 130.46, 129.60, 128.85, 128.51, 125.66, 123.69, 
121.35, 93.43, 87.91, 47.11, 14.74. LC-MS: tR: 8.33 min (linear gradient 10-90% in 
13.5 min), m/z = 320.0 [M+H]+, 274.0 [M-CO2+H]+ 
 
16a: Prepared from 14 (516 mg, 2 mmol) and glycine  (157 mg, 
2.1 mmol) according to the general condensation procedure to 
yield to title compound as white solid (440 mg, 1.41 mmol, 70%). 1H NMR (400 MHz, 
DMSO) δ 13.13 (s, 1H), 7.85 (d, J = 8.3, 1H), 7.52 (d, J = 2.2, 1H), 7.48 (d, J = 7.1, 
2H), 7.44 – 7.39 (m, 3H), 7.38 – 7.32 (m, 1H), 5.32 (s, 2H), 4.28 (s, 2H). 13C NMR 
(101 MHz, DMSO) δ 168.92, 166.89, 166.80, 163.59, 136.02, 134.06, 128.54, 
128.14, 127.82, 125.25, 123.37, 120.95, 109.26, 70.22. LC-MS: tR: 7.10 min (linear 
gradient 10-90% in 13.5 min), m/z = 312.2 [M+H]+, 265.9 [M-CO2+H]+ 
 
15: Prepared from 14 (516 mg, 2 mmol) and alanine  (187 mg, 2.1 
mmol) according to the general condensation procedure to yield to 
title compound as white solid (509 mg, 1.56 mmol, 78%). 1H NMR (400 MHz, DMSO) 
δ 13.04 (s, 1H), 7.82 (d, J = 8.3, 1H), 7.51 – 7.45 (m, 3H), 7.44 – 7.38 (m, 3H), 7.38 – 





















MHz, DMSO) δ 171.09, 166.80, 166.75, 163.56, 136.04, 133.94, 128.81, 128.54, 
128.46, 128.42, 128.12, 127.78, 127.57, 125.17, 123.28, 120.96, 109.14, 70.19, 
46.93, 14.87. LC-MS: tR: 7.56 min (linear gradient 10-90% in 13.5 min), m/z = 326.1 
[M+H]+, 280.0 [M-CO2+H]+ 
 
16b: Prepared from 14 (516 mg, 2 mmol) and β-alanine  (187 mg, 
2.1 mmol) according to the general condensation procedure to 
yield to title compound as white solid (500 mg, 1.54 mmol, 77%). 1H NMR (400 MHz, 
DMSO) δ 12.35 (s, 1H), 7.77 (d, J = 8.3, 1H), 7.49 – 7.31 (m, 7H), 5.29 (s, 2H), 3.76 
(t, J = 7.3, 2H), 2.59 (t, J = 7.3, 2H). 13C NMR (101 MHz, DMSO) δ 172.09, 167.19, 
163.32, 136.08, 134.20, 128.82, 128.53, 128.40, 128.11, 127.77, 127.55, 124.87, 
123.59, 120.52, 108.94, 70.14, 33.58, 32.43. LC-MS: tR: 7.26 min (linear gradient 10-
90% in 13.5 min), m/z = 326.0 [M+H]+, 308.2 [M-H2O+H]+, 266.0 [M-CH2CO2+H]+ 
  
16e: Prepared from 10 (496 mg, 2 mmol) and phenylalanine  
(347 mg, 2.1 mmol) according to the general condensation 
procedure and purified by HPLC yielding the title compound as off white foam (639 
mg, 1.6 mmol, 80%). 1H NMR (400 MHz, DMSO) δ 13.30 (bs, 1H), 7.91 (d, J = 6.6, 
2H), 7.83 (d, J = 8.0, 1H), 7.62 – 7.56 (m, 2H), 7.43 (d, J = 4.8, 3H), 7.19 – 7.14 (m, 
4H), 7.14 – 7.07 (m, 1H), 5.16 (dd, J = 4.7, 11.5, 1H), 3.52 (dd, J = 4.7, 14.1, 1H), 
3.43 – 3.31 (m, 1H). 13C NMR (101 MHz, DMSO) δ 169.99, 166.43, 166.34, 137.43, 
137.27, 131.70, 131.29, 129.80, 129.58, 128.81, 128.73, 128.33, 126.59, 125.77, 
123.77, 121.38, 93.66, 87.77, 53.17, 33.98. LC-MS: tR: 9.42 min (linear gradient 10-
















17c: Prepared from 10 (496 mg, 2 mmol) and D-alanine  (187 mg, 
2.1 mmol) according to the general condensation procedure and 
purified by recrystalization from hot water yielding the title compound as white solid 
(506 mg, 1.6 mmol, 80%).  1H NMR (400 MHz, DMSO) δ 13.15 (s, 1H), 8.04 – 7.98 
(m, 2H), 7.93 (d, J = 7.7, 1H), 7.66 – 7.60 (m, 2H), 7.50 – 7.45 (m, 3H), 4.89 (q, J = 
7.2, 1H), 1.56 (d, J = 7.3, 3H). 13C NMR (101 MHz, DMSO) δ 170.90, 166.46, 166.36, 
137.30, 131.89, 131.71, 130.46, 129.59, 128.84, 128.53, 125.66, 123.69, 121.36, 
93.44, 87.91, 47.13, 14.75. LC-MS: tR: 8.31 min (linear gradient 10-90% in 13.5 min), 
m/z = 320.0 [M+H]+, 273.9 [M-CO2+H]+ 
 
16c: Prepared 14 (496 mg, 2 mmol) and D-alanine  (187 mg, 2.1 
mmol)  according to the general condensation procedure and 
purified by HPLC to yield the title compound as white solid (280,7 mg, 0.86 mmol, 
43%). 1H NMR (400 MHz, DMSO) δ 13.05 (bs, 1H), 7.82 (d, J = 8.3, 1H), 7.51 – 7.45 
(m, 3H), 7.44 – 7.38 (m, 3H), 7.38 – 7.32 (m, 1H), 5.32 (s, 2H), 4.83 (q, J = 7.3, 1H), 
1.53 (d, J = 7.3, 3H). 13C NMR (101 MHz, DMSO) δ 171.06, 166.78, 166.73, 163.55, 
136.03, 133.93, 128.53, 128.11, 127.77, 125.16, 123.26, 120.97, 109.13, 70.17, 
46.90, 14.85. LC-MS: 16c did not ionize, preventing acquisition of the LC-MS 
specrum  
 
18b: Prepared from 17c (133 mg, 0.35 mmol) according to the 
general hydrogenation procedure and purified by HPLC to yield 
the title compound (84 mg, 0.26 mmol, 74%)  1H NMR (400 MHz, DMSO) δ 7.74 (d, J 
= 7.7, 2H), 7.63 (d, J = 8.5, 1H), 7.28 – 7.18 (m, 4H), 7.15 (t, J = 6.9, 1H), 4.85 (q, J = 


















(101 MHz, DMSO) δ 171.24, 167.37, 167.23, 149.55, 140.87, 134.75, 131.84, 
129.29, 128.52, 128.36, 126.09, 123.38, 123.26, 47.12, 37.19, 36.75, 14.93. LC-MS: 
tR: 7.97 min (linear gradient 10-90% in 13.5 min), m/z = 324.1 [M+H]+, 278.1 [M-
CO2+H]+ 
 
 18c Prepared from 17e (138 mg, 0.35 mmol) according to 
the general hydrogenation procedure to yield the title compound (141 mg, 0.35 mmol, 
quant). 1H NMR (400 MHz, DMSO) δ 7.69 (d, J = 7.5, 2H), 7.60 (d, J = 8.2, 1H), 7.28 
– 7.06 (m, 10H), 5.12 (dd, J = 4.8, 11.7, 1H), 3.50 (dd, J = 5.1, 14.9, 2H), 3.42 – 3.34 
(m, 1H), 3.05 – 2.96 (m, 2H), 2.93 – 2.84 (m, 2H).13C NMR (101 MHz, DMSO) δ 
170.24, 167.28, 167.14, 149.66, 140.84, 137.41, 134.81, 131.21, 129.10, 128.74, 
128.65, 128.44, 128.33, 128.29, 126.57, 126.02, 123.41, 123.27, 52.99, 37.08, 
36.57, 34.06. LC-MS: tR: 9.00 min (linear gradient 10-90% in 13.5 min), m/z = 400.0 
[M+H]+,354.0 [M-CO2+H]+ 
 
18a Prepared from 17c (99.5 mg, 0.31 mmol) according to the 
general hydrogenation procedure to yield the title compound (93 
mg, 0.29 mmol, 94%).1H NMR (400 MHz, DMSO) δ 13.14 (s, 1H), 7.95 – 7.52 (m, 
3H), 7.39 – 7.10 (m, 5H), 4.86 (d, J = 4.8, 1H), 3.06 (s, 2H), 2.92 (s, 2H), 1.55 (d, J = 
4.5, 3H). 13C NMR (101 MHz, DMSO) δ 171.13, 167.25, 167.11, 149.46, 140.79, 
134.67, 131.68, 129.13, 128.43, 128.27, 125.99, 123.31, 123.19, 46.99, 36.99, 
























/9:D=.Data collection and integration statistics for Rit1. The statistics in parentheses 
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!A?MJ=.The ranking of primary fragment hits obtained from TINS NMR screening 








!A?MJ=.The experimentally observed nitroxide to amide proton distances (Å) are plotted 
against the back-calculated distances after optimizing the nitroxide position in XPLOR-NIH 
(see Methods). The solid line indicates the ideal correlation, dashed lines represent ± 3 Å 
error limits (Q =0.059). Amide protons of which the resonances were not affected by the 
nitroxide, were given a lower limit of 21 Å.

!A?MJ= . The loop consisting of residues 42-57 was optimized using PRE’s observed 
from the nitroxide radical. In blue is the original crystal structure, yellow stick representing the 
position of the GDP-spin label, yellow sphere shows the magnesium ion and in the grey is 

































!A?MJ=.The two aliphatic resonances, M1 and M2 of 18c are shown. Other resonances 
M3 and M4 could not be assigned due to overlap with the other buffer components.


!A?MJ= . The saturation transfer experiments were performed as described in the 
experimental section. The plot of the intensity vs saturation time is depicted showing the 
saturation transfer rate for various protons of 18cThe reduction in the intensity was caused 
by saturation transfer by irradiating at -0.5 ppm. The saturation time was varied from 50 ms 





















!A?MJ= .Comparison of back calculated and observed distances averaged over top 10 
structures with error limits of ± 3A shown by dashed lines. Solid line represents the perfect 
correlation. The blue squares indicate the lowest docking solutions obtained by treating the 
intermolecular restraints as two separate sets. The red diamonds shows the distances 
obtained by simulation consisting of all inter-molecular PRE distance restraints in one set.  
As only two PRE restraints were available for the acidic moiety of 18c, the force constant for 
PREs was increased from 3.0 to 90.0 to get a significant energy penalty whenever the PRE 
restraints were not fulfilled.

332 334 336 338 340 342
B, mT

!A?MJ= .The X-band cw EPR measurements on GDP-spin label have been performed 
using an ELEXSYS E680 spectrometer (Bruker, Rheinstetten, Germany) equipped with a 
rectangular cavity. A modulation frequency of 100 kHz was used. Measurements were done 
at temperature of 20°C, using 6.31 mW of microwave power and modulation amplitude of 0.5 
G.
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Figure S11. The depiction of the chemical structure of the GDP-spin label probe used in the 
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Target identification, validation and production of protein for crystallography, 
nucleotide exchange assays and NMR screening were performed by Masakazu 
Kobayashi (Galapagos NV). NMR screening was performed at ZoBio BV. Johan 
Hollander (ZoBio BV) helped to set-up the NMR screen. Eiso AB and Caroline Loch 
(ZoBio BV) performed the computational analysis to generate fragments hits. Francis 
Figaroa (ZoBio BV) assisted with the compound preparations for TINS NMR screen.  
Anna A. Rzepiela (Pyxis discovery) performed the computational studies for analogs. 
Crystallography studies on the target and target-ligand complexes were performed by 
F. Hoedemaker and Linda Manning (KeyDP BV). Synthesis of compounds at various 
stages was done by Adriaan W.Tuin (Leiden University). Peter H.J. Keizers (Leiden 
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ABSTRACT   
 
An efficient way to rapidly generate protein-ligand co-structures based on solution-
NMR using sparse NOE data combined with selective isotope labeling is presented. 
A docked model of the 27 kDa N-terminal ATPase domain of Hsp90 bound to a small 
molecule ligand was generated using only 21 intermolecular NOEs which uniquely 
defined both the binding site and the orientation of the ligand. The approach can 






















 The availability of 3D structural information on protein-ligand complexes has become 
an important driver to guide the pre-clinical stages of drug discovery. Structure based 
drug design (SBDD) has enabled the development of a wide array of drugs that are 
currently on the market such as inhibitors of the HIV protease and kinases.1,2 In the 
past 15 years fragment-based drug discovery (FBDD), which uses very small, soluble 
drug fragments as starting points to develop new medicines, has become 
widespread. Due to their small size, fragments typically bind the target with low 
affinity (KD > 10 µM). The development of weak fragment hits to more potent lead-like 
structures is 2-3 times more successful when 3D structural information is available.3 
Thus the success of both SBDD and FBDD is heavily dependent upon the availability 
of structural information. Presently both approaches are primarily driven by X-ray 
crystallography. Crystallography has the advantage that when successful, it is both 
rapid and high resolution. However, there are a number of cases in which 
crystallography is not successful such as when crystals are not available, the crystal 
packing precludes access to the active site or most commonly, weakly binding 
fragments simply do not give rise to electron density. In the latter case there can be 
many causes including insufficient occupancy of the binding site or multiple possible 
binding orientations. In principle, NMR-based solution methods can also generate 
atomic resolution structural information and NMR has indeed successfully supported 
FBDD campaigns.4 Since NMR is extremely sensitive to weak protein-ligand 
interactions, it should be applicable exactly where crystallography is least effective, 
i.e. for complexes of weakly binding ligands. However, traditional NMR approaches 
involving uniform isotopic labeling are labor intensive and limited to proteins of 





  In drug discovery it is often the case that the 3D structure of a target or a 
homologous protein is available. If the resonance assignment of such a protein is 
available, mapping of chemical shift perturbations (CSPs) onto the 3D structure is a 
simple, fast procedure that can provide low resolution information about a small 
molecule binding site.5 CSP mapping is most commonly accomplished through 
analysis of  15N- or 13C-edited heteronuclear correlation spectra of the protein. 
However, the interpretation of  1H-15N or 1H-13C HSQC CSPs becomes ambiguous 
when the chemical shift perturbations are caused by changes in protein dynamics or 
a shift in equilibrium between two (or more) conformations. Various computational 
methods primarily based on chemical shift perturbation analysis are most successful 
at determining the location of the binding site to low resolution. The precise nature of 
the intermolecular contacts are well beyond the capabilities of structural analysis 
based on CSPs.6,7  In principle a limited set of intermolecular NOEs could provide 
sufficient information to determine the orientation and binding mode of a small 
molecule bound to a protein. Indeed, a number of approaches that use a combination 
of amino acid selective labeling and intermolecular NOEs have been proposed.8-10 
While these are quite powerful, they suffer from one or more of the following 
limitations: (i) requirement for a priori knowledge of the ligand binding site in order to 
be able to efficiently select the right combination of residues to label, (ii) requirement 
for a large number of intermolecular NOE contacts, (iii) the resonance assignment 
uses the pattern of chemical shift perturbations induced by ligand binding and 
therefore may not be robust and (iv) requirement for extensive calculations to 
generate structures that match the experimental data. We sought an NMR based 




support elaboration of “weakly” binding fragments to target proteins that met the 
following criteria: widely applicable to small and large proteins, rapid (2-3 weeks per 
complex), standard solution conditions and NMR experiments, requires samples that 
can be easily made and the data interpretation is unambiguous. Here, we 
demonstrate such a method based on selective ILV methyl-labeling and a sparse set 
of intermolecular NOEs.  
 
RESULTS AND DISCUSSION 
 The approach as outlined in Figure 1, requires an NMR sample of the protein in 
which the target protein is highly deuterated and where NMR visible, isotopic labels 
have been introduced along the backbone and selectively at ILV sidechains as 
described by Tugarinov and Kay.11 Standard, through-bond double and triple-
resonance NMR spectra are used to obtain the backbone and ILV sidechain 
resonance assignments of the protein. The ligand is then titrated into the protein in 
small increments such that the shift in both backbone and sidechain resonance 
positions can be readily followed using 2D heteronuclear correlation spectra. Once 
binding of the compound to the protein is saturated, 13C- and 15N-edited NOESY-
HSQC spectra are recorded to generate a set of intermolecular NOEs between the 
ligand resonances and ILV methyl groups as well as the backbone amide protons of 
the protein. A known 3D structure or structures of the protein target (or a homology 
model) is then used for molecular docking using HADDOCK to obtain the protein-
ligand structure based solely on the intermolecular NOE restraints.12 Given that the 
isotopic labeling method has been used to obtain assignments for large proteins, it is 
likely that the proposed scheme can also be used to determine experimentally 




molecule complexes in an efficient yet reliable manner.11,13-15 Here the approach is 
illustrated using the moderately sized 27 kDa N-terminal domain of the molecular 
chaperone heat shock protein 90 (Hsp90), a known cancer target. 
 
Figure 1.  A flowchart scheme to illustrate the number of steps involved in the determination 
of the model protein-ligand complex by solution NMR based on the sparse NOE data using 
ILV methyl labeling approach.  
 
The N-terminal domain of Hsp90 (9-233) was isotopically labeled in E. coli 
according to the published procedure.11 Heteronuclear correlation experiments 
yielded highly resolved spectra with excellent sensitivity in which all expected methyl 
peaks can be observed (Figure 2). The triazine 1 had been discovered as a ligand of 
Hsp90 in a target immobilized NMR screen (TINS) of a fragment library constructed 
from commercially available compounds.16,17 The binding of 1 to Hsp90 was 
confirmed using surface plasmon resonance technology and the equilibrium KD was 
determined to be 58 µM via fitting to a 1:1 binding model (data not shown). We 
investigated the effect of 1 binding to the protein by recording a high-resolution CT-




2).18,19 The methyl chemical shift perturbations are clear evidence of the binding of 1 
to Hsp90. The peak pattern in the bound state is suggestive of a folded protein 
indicating that the binding is specific and does not result in protein denaturation or 
other undesirable affects. Surprisingly, the majority of the methyl resonances are 
affected by the binding of 1 and a similar pattern was observed in the [1H, 15N]-HSQC 
(not shown). Using the sequential assignment determined below, the methyl and 
backbone amide chemical shift perturbations (CSPs) have been mapped onto the 
crystal structure of Hsp90 (Figure 3). Although the CSPs surround the known ATP 
binding site, residues far from the site are also significantly affected. The widespread 
changes in the spectrum of Hsp90 could be indicative of conformational changes in 
the protein induced or stabilized by the binding of compound 1. Indeed, 
conformational changes have been observed for a number of ligands binding to 
Hsp90.20 Thus it can be difficult to determine the ligand binding site simply on the 
basis of CSPs (see below). Furthermore, the orientation of the ligand within the 
binding site, and therefore the nature of the protein-ligand interactions, is not defined 





Figure 2. CT- [1H,13C] HSQC spectra of an ILV methyl protonated sample of deuterated N-
terminal domain of  Hsp90 recorded in the absence (in red) and in the presence of 1 (in 
green) at a protein to ligand ratio of 1:6. Significant chemical shift perturbations for various 
methyl groups are seen clearly in the presence of 1, indicative of binding. 
 

Figure 3.The methyl (yellow) and amide (red) chemical shift perturbations caused by the 
presence of 1 are mapped on the crystal structure of Hsp90 (PDB 1YER). The figure was 
created in PyMOL.21 
 
The sequential backbone assignment of Hsp90 is available (e.g. BMRB 5355) 
but was confirmed by analysis of TROSY-based HNCACB and HNcoCACB NMR 




assigned, including 87% of the ILV residues. The methyl resonances were 
subsequently correlated with the intraresidue Cα and Cβ assignments by a CCH-
TOCSY experiment. Of the ILV residues that had been sequentially assigned, 92% of 
the ILV methyl assignments were obtained in a straightforward manner. It is not 
essential to obtain all ILV methyl assignments since only those within the binding site 
will give rise to intermolecular NOEs. Based on the crystal structure of a complex of 1 
with Hsp90 (see below), all methyl groups that are within NOE distance (8 Å using a 
highly deuterated protein) to the ligand have been assigned using only data from 
these three experiments. Stereospecific methyl assignments for Leu and Val 
residues were obtained by producing a 10% 13C labeled sample and CT-HSQC 
analysis as described previously.22 
 
Figure 4.  A] Representative strips from the 3D 13C- and 15N-edited NOESY-HSQC spectra 
of methyl protonated {I(13CH3, δ1 only), L(13CH3,12CD3), V(13CH3,12CD3)} U-[15N,13C,2H] 
Hsp90 in the presence of 1. The intermolecular NOEs between the methyl groups of the 
protein (L107MD1, L107MD2) and the ligand H1, H2, H3 groups are circled. The strips for 
residues I96 and G97 from a 15N-edited NOESY-HSQC spectrum are shown from which 
intermolecular NOEs to the H3 group of 1 are circled. The frequencies (ppm) of 1H and 13C or 
15N nuclei are shown at the bottom and the top of the strips respectively. B] The structure 




3D 13C-edited and 15N-edited NOESY-HSQC spectra were recorded on the 
protein-ligand complex in order to detect intermolecular NOEs.23,24 Due to the 
selective labeling scheme employed, there was minimal overlap amongst the protein 
resonances and therefore intermolecular NOEs were unambiguously assigned. 
Selected strips from the 13C-edited NOESY-HSQC and 15N-edited NOESY-HSQC 
spectra exhibiting intermolecular NOEs from the ligand are shown in Figure 4A. A 
total of 21 intermolecular NOEs were identified between resonances of 1 and protein 
residues including three to amide protons (I96, G97 and M98) and 18 NOEs to 
methyl groups (L107, L103, V150, V186 and I96). The peak intensities from the 
intermolecular NOEs were converted to distances and used as restraints to carry out 
the docking of the ligand using HADDOCK (See experimental section for more 
information).12  
   Typical of many pharmaceutical targets, a crystal structure of apo-Hsp90 (PDB 
1YER) is available in the PDB. This structure was the starting point for the 
experimentally restrained docking procedure. We performed HADDOCK calculations 
using only the apo-Hsp90 structure and 21 intermolecular-NOE distances as 
unambiguous restraints (Table 1).12  The lowest energy cluster exhibited a 
HADDOCK score and minimal restraint violation energy of -7.0 and 3.8 kcal/mol 
respectively, whereas the next ligand cluster exhibited a HADDOCK score of 3.4 and 
minimal restraint violation energy of 20.0 kcal/mol. The difference between the 














Table 1. Intermolecular NOE distance restraints included into HADDOCK calculations are 













H1 I96 HD1 3.8 
H1 L103 HD+ 4 
H1 L107 HD1 4.3 
H1 L107 HD2 4 
H1 V150 HG1 3.8 
H1 V150 HG2 3.8 
H1 V186 HG2 4.3 
H2 I96 HD1 4 
H2 L103 HD+ 5 
H2 L107 HD1 4.6 
H2 L107 HD2 4 
H2 V150 HG1 5.3 
H2 V186 HG2 5.3 
H3 L103 HD+ 4.9 
H3 L107 HD1 3.9 
H3 L107 HD2 3.6 
H3 V150 HG1 4.8 
H3 L186 HG2 5 
H3 I96 HN 4 
H3 G97 HN 4 
H3 M98 HN 4 
 
A crystal structure of the complex of 1 with Hsp90 was available in the PDB (3B24).25 
In 3B24 there are two protein molecules in the asymmetric unit and although 1 is 
bound in the same site in each, it is rotated by approximately 180o in the different 
structures (Figure 5A). Superposition of the protein in the three structures (NMR 
model and two crystal structures) indicates that the sparse NOE method defines the 
binding site of the ligand uniquely and accurately. Most Hsp90 ligands form critical 
hydrogen bonds to residues D93 and T184 and these are present in both the X-ray 
structures and the NMR model. The orientation of 1 in the NMR based model is quite 
similar to one of the orientations in the asymmetric unit of the crystal structure (1.7 Å 
rmsd). In the NMR model, the orientation of 1 is defined by a network of 3 




G97 and M98 (Figure 5B) and is thus unambiguous.  Interestingly, PDB entries 2WI2 
and 2WI3, are structures of a similar triazine bound to Hsp90 in which two 
orientations differing by a 180o axial rotation are found. In this case the different 
orientation was dependent on whether soaking or co-crystallization was used to form 
the complex.26 Taken together the crystal structures suggest that there are two or 
more low energy conformations for the complex of these simple triazines with Hsp90. 
In contrast, the NMR data indicate that in solution, there is one predominant 
conformation and this is likely to be the most physiologically relevant. Importantly, 
despite the moderate number of intermolecular restraints, the NMR model defines 
precisely the same binding site as the crystal structure and the critical intermolecular 
hydrogen bonds suggesting that in addition to being fast, the method is robust. 
 
Figure 5. A] Overlay of the lowest energy HADDOCK model of 1 bound to Hsp90 with  a 
crystal structure of the complex (PDB 3B24) in which 1 binds in two orientations (docked 
model- magenta, 3B24: green and sky blue). The orientation of 1 in the NOE-based model is 
similar to one of the binding modes (seen in sky blue color) of the ligand in PDB entry 3B24. 
B] The orientation of 1 in the docked model is largely determined by the three intermolecular 
NOEs observed between the H3 group of the ligand and HN of I96, G97 and M98 shown in 
pink within the protein. The figure was created in PyMOL.21 
 
    Numerous groups have attempted to use CSPs to determine the structure of 
protein-ligand complexes.7,27 We used the ability of HADDOCK to include CSPs as 




using the most significant methyl and backbone amide CSPs (Figure 6). The 
HADDOCK calculations generated 2 clusters whose HADDOCK scores were similar 
and significantly lower than others. Interestingly, the clusters are both located at the 
binding site of 1 defined in both the NOE model and the crystal structures. However, 
despite the fact that electrostatics were used during the HADDOCK calculation, the 
hydrogen bonds to D93 and T184 are not present. In fact, the amine group of 1 is 
pointing away from these residues. 

Figure 6.Overlay of the lowest energy HADDOCK model structures of 1 bound to Hsp90 
obtained using the most significant methyl and backbone amide chemical shift perturbations 
(Δδi > Δδavg + 2 x standard deviation). Two clusters of 1 are observed which have similar 
HADDOCK score. A] Overlay of the two structures from one of the clusters (magenta and sky 
blue) with NOE-derived docked model shown in orange. B] Overlay of the two structures 
from the other cluster (pink and dark green) with NOE-derived docked model shown in 






Figure 7. Overlays of the lowest energy HADDOCK model structures are shown when 1 is 
docked with various N-term Hsp90 structures with different sidechain conformations (shown 
as lines) in the PDB (1YER- yellow, 1OSF-orange, 2QF6-magenta and 3B26-grey). The 
ligand is found to bind in the same binding spot in comparison with the X-ray structure, 
irrespective of the conformational flexibility of the helix formed by residues 100-124 seen in 
the various PDB structures. The figure was created in PyMOL.21  
 
  Frequently ligand binding is accompanied by a conformational change in the 
protein. Conformational rearrangement of residues 100-124, which are in close 
proximity to the ligand binding site of Hsp90, has been observed for a number of 
ligands including in the two structures in the unit cell of 3B24 (Figure 5A). To 
investigate any possible influence of conformational rearrangement on the structures 
calculated from NMR data, we selected 3 different Hsp90 structures which differ in 
the conformation of residues 100-124 for docking using HADDOCK.12 The binding 
site and orientation of the ligand cluster in each of the 3 different Hsp90 structures 
was very similar to that determined using the apo-protein (Figure 7). Importantly, the 
intermolecular hydrogen bonds to D93 and T184 are conserved in all 4 
experimentally constrained docking structures. This data suggests that, at least for 




determining the essential features of a small molecule-protein complex even if those 
changes are unknown.    
CONCLUSION  
 
 The method presented here appears to be capable of generating reliable protein-
ligand structures in a quick and efficient manner. We have shown that a universal 
selective labeling scheme can be used to rapidly identify sufficient numbers of 
restraints for a small molecule ligand weakly bound to protein. Moreover, universal 
labeling precludes the necessity for a priori knowledge of the ligand binding site. 
However, the present method depends on the availability of selectively labeled, 
deuterated protein which can only be produced in E. coli. Note that the 3 NOEs 
involving backbone amide protons of the protein were critical for orienting 1 in the 
protein-ligand complex. This observation suggests that, at least in some cases, the 
use of exclusively methyl labeled protein could result in the loss of important 
constraints for the calculation procedure. Another obvious limitation is the 
requirement for methyl groups at the ligand binding site. Although ILV residues tend 
to be well located in proteins and clearly Hsp90 is a good example of this, it is not 
always the case.13 However, it is also possible to selectively label all methyl 
containing residues providing even more complete coverage of protein structures and 
ligand binding sites.28 While we have used standard, through-bond NMR techniques 
for resonance assignment here, recently steps towards automating the assignment of 
methyl resonances based either on intramolecular NOEs and/or through-space 
paramagnetic effects have been taken.29 Implementation of selective methyl labeling 
in conjunction with automated resonance assignment should enable structure 
determination of complexes involving reasonably large proteins up to 75 kDa. We 








    A methyl protonated {I(13CH3, δ1 only), L(13CH3,12CD3), V(13CH3,12CD3)} U-
[15N,13C,2H] sample of N terminal domain (9-233) of Hsp90 was obtained by protein 
overexpression from a culture of E. coli BL21 (DE3) cells transformed with the 
plasmid pQTEV as described.11 The protein was  expressed in 1 L D2O M9 medium 
supplemented with 2 g/L of U-[13C, 2H]-glucose (Sigma) as the main source of carbon 
and 0.3 g/L of 15NH4Cl (Sigma) as the nitrogen source. One hour prior to induction at 
~0.5 OD, 50 mg of 2-keto-3,3-d2-1,2,3,4-13C-butyrate and 100 mg of 2-keto-3-methyl-
d3-3-d1-1,2,3,4-13C butyrate (13C labeled α-ketoisovalerate deuterated at the β-
position and with one of the methyl groups - 12CD3) were added to growth medium. 
The expression of the protein was induced by the addition of 1 mM IPTG for 16 hours 
at 18°C. The protein was purified on Ni-Hitrap FF (GE Lifescience) followed by 
purification on a superdex G75 gel filtration column (GE Lifescience). The seven-
histidine tag was removed by proteolytic digestion with TEV protease (Invitrogen) 
according to the manufacturer recommended buffer condition. The cleaved tag and 
the TEV protease were removed by affinity purification on Ni-Hitrap FF, and 
subsequently the buffer of Hsp90 (9-233) was exchanged to 20 mM sodium 
phosphate pH 7.5, 50 mM NaCl. The NMR sample was 0.7 mM in protein, 95% H20, 
5% D20, 20 mM sodium phosphate, pH 7.5, 50 mM NaCl. The NMR sample on the 
Hsp90-1 complex was obtained by addition of 6 equivalents of 1 to the protein. The 
pH of the sample was adjusted carefully within +/- 0.05 units  of 7.5 after addition of 




labeled sample and CT-HSQC analysis as described. 22    
Compound 1 was purchased from Maybridge, catalog number -! 
NMR backbone sequential assignments and ILV methyl assignments 
  In order to detect binding of 1 to Hsp90, a CT- [1H,13C] HSQC spectrum of 0.7 mM 
protein and protein plus ligand (1:6 ratio) was recorded on a Varian 800 MHz 
spectrometer equipped with a cryogenic probe. The chemical shifts of 1 in the bound 
state were also followed by acquiring 1D 1H proton spectrum in the presence of 
protein at different protein plus ligand ratios (1:0, 1:2, 1:4 and 1:6). 
  In order to perform sequential assignment of the backbone resonances and 
correlate them to the intraresidue ILV methyl resonances of the Hsp90-1 complex, 
the following experiments were acquired at 298K on 600MHz four-channel Bruker 
DMX NMR spectrometer equipped with a TXI cryo-probe; [1H,15N]-HSQC, trHNCACB 
recorded with (2048x80x110) in (1HN,15N,13C) dimensions, trHNcoCACB  recorded 
with (2048x80x180) in (1HN,15N,13C) dimensions with a recycle delay of 1s and with 
16 scans/FID.30,31 To correlate the backbone Cα and Cβ frequencies to the 
intraresidue methyl resonances of ILV residues, a CCH-TOCSY experiment was 
recorded with (2048x80x152) in (1Hm,13Cm,13C) dimensions with a recycle delay of 1s 
and with 8 scans/FID. The CCH-TOCSY pulse sequence was obtained by 
modification of a standard (H)CCH-TOCSY pulse sequence by removal of the initial 
INEPT pulses, addition of deuterium decoupling during the t1 and t2 period, starting 
with a direct carbon excitation pulse,  followed by a DIPSI-3 TOCSY transfer 
sequence and final detection on the methyl protons. The optimal mixing time for the 
TOCSY sequence was found to be 23.3 ms.32   
  A series of 2D 1H-1H NOESY planes with mixing time between 100-600 ms were 




peak intensity. The optimal mixing time was defined to be a balance of being able to 
detect long range NOEs and spin diffusion and was found to be 400 ms. In order to 
observe intermolecular NOE cross peaks between the ligand and the protein, a 13C-
edited NOESY-HSQC (1024x40x160 points in 1H,13C,1H respectively) and a 15N-
edited NOESY-HSQC (1024x44x160 points in 1H,15N,1H respectively) were recorded 
with , mixing time of 400 ms and a recycle delay of 1s and with 16 scans/FID 
respectively.33-36 The NOESY experiments were acquired at 298K on a 900 MHz 
four-channel Bruker DMX spectrometer equipped with pulsed field gradient, 
conventional room-temperature triple resonance probe. The cross-peak 
volumes/peak intensities from the intermolecular NOEs were converted to distances 
based on the equation V=C/bn  (V= cross-peak volume/peak intensity, C is a 
constant, b is the upper distance bound and n is an exponent 4).37 The acquired 
NMR data was processed using the NMRpipe/NMRDraw software package and 
visualized in Sparky.38,39 The backbone assignment process was guided by the 
predicted chemical shifts calculated by SHIFTX in the automatic assignment program 
MARS using PDB 1YER as input.40,41 The use of ILV methyl labeling is attractive for a 
number of reasons including: (i) the favorable relaxation properties of methyl groups 
so that NMR spectra, even for larger systems, are of higher sensitivity and 
resolution,14,42 (ii) the well-dispersed distribution of the methyl groups throughout the 
protein structure and particularly at ligand binding sites,43  (iii)  restriction of the NMR 
analysis to the backbone and sidechain resonances of ILV methyl groups of the 
protein simplifies the process and allows unambiguous identification of intermolecular 







Throughout the docking procedure using HADDOCK, 1000 protein structures were 
used for initial rigid body docking. Explicit solvent refinement was performed on 200 
structures after initial docking iterations. The final docking solutions were selected by 
clustering of the structures and analysis of the HADDOCK scores.  The Hsp90 
structures used in HADDOCK calculations to investigate the conformational 
rearrangement of the helix formed by residues 100-124 are derived from a number of 
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NMR Spectroscopy to Investigate Protein-Ligand Interactions 


NMR is a powerful and versatile tool with methods that are used for a 
variety of applications in fragment based drug discovery (FBDD). Common 
applications involve 1. ligand screening to generate hit matter (Chapters 2 and 3) 2. 
hit confirmation or hit validation (Chapters 2 and 3) and 3. obtaining atomic resolution 
3D structures of the protein-ligand complexes to guide hit to lead development 
(Chapters 3 and 4). FBDD involves the discovery of weak affinity fragments, which 
are later optimized into more potent lead compounds. The availability of 3D structural 
information about the interactions that a small molecule fragment makes within the 
binding site of a protein target is critical during the fragment hit-lead optimization 
stage. SBDD (structure based drug design) is considered to be the main driver for 
the development of many marketed drugs.1  
The goal of the work described in this thesis was to develop and implement 
efficient NMR methods that are capable of providing 3D structural information on 
protein-ligand complexes and applicable in the early stages of the drug discovery 
projects. Both X-ray crystallography and NMR based methods generate atomic 
resolution structural information and successfully support SBDD and FBDD. 
Especially as NMR based methods are sensitive towards weak protein-ligand 
interactions, they should be applicable where X-ray crystallography is least effective 
i.e. for weakly bound ligands. However, traditional NMR approaches involving uniform 
isotopic labeling are labor intensive and limited to proteins of moderate size (e.g., < 
30-40 kDa) and have therefore not been widely adopted in drug discovery. In this 





Chemical Shift Perturbation Analysis on Protein-Ligand Complexes 
NMR based chemical shift perturbation (CSP) analysis offers a fast and robust 
means to obtain low resolution structural information on the protein-ligand complex. 
CSPs are routinely employed to determine the binding location of the ligand. The pre-
requisite for determination of the ligand binding site from CSP analysis is the 
availability of the resonance assignment and the 3D structure (NMR or X-ray) of the 
target protein. When a ligand is titrated, the amide group of amino acids within the 
protein that are close to the ligand will experience a change in their local chemical 
environment. A chemical shift map is generated which allows identifying those amide 
groups whose environment is most affected due to the binding of a ligand. The map 
will also include those residues that are indirectly affected by ligand induced changes 
in the protein. These CSPs result mainly from the sensitivity of amide groups to pH 
and/or small changes that occur in the hydrogen bonding patterns of protein 
backbones upon ligand binding.3,4,5  
CSP based determination of the binding site was employed in Chapters 2 and 
3.  CSP analysis resulted in locating the binding sites of a DNA oligonucleotide and 
three fragments (Chapter 2). The CSP mapping clearly showed that the binding site 
for the fragment hits was the same as that of the oligonucleotide. In the absence of 
high resolution co-structures of TELETS-fragments and based solely on CSP data, we 
were able to deduce that fragments were able to bind to the DNA binding interface. 
This subsequently explained the disruption of the protein-DNA complex by fragments 
in gel-shift assays.   
The absence of co-structures of Rit1 with inhibitory compounds (Chapter 3), 
necessitated the use of the CSP based approach to understand the mechanism of 




determine the binding site of the ligand with the highest affinity for Rit1. Interestingly, 
the CSP mapping for the ligand indicated multiple binding sites on Rit1. In this case, 
the primary binding site was close to the GDP nucleotide binding pocket and a 
secondary site was close to a loop that was missing from the Rit1-GDP crystal 
structure (PDB 4KLZ). The secondary site might have been a result of a 
conformational rearrangement caused upon binding of the ligand or influenced by the 
flexibility of the loop of the protein.6 As the CSP data suggested the possibility of two 
binding sites, further structure restraints (described in the paramagnetic NMR section 
below) were necessary in order to precisely define the ligand binding to the protein 
and to shed light on the mechanism of inhibition of nucleotide exchange. 
In conclusion, the use of CSP data analysis in TELETS small molecule 
discovery work assisted in the determination of the binding site for ligands and the 
DNA oligonucleotide. CSP data also explained the disruption of the protein-DNA 
complex by fragments. These fragments represent valuable starting points for 
developing potent lead compounds. Although the CSP data on the Rit1-inhibitor 
complexes described in Chapter 3 was informative, they gave ambiguous results. 
This was attributed to the presence of two distinct binding sites for the inhibitor on the 
protein surface. In Chapter 4, CSP analysis was used to determine the binding of a 
fragment hit to a selective methyl group labeled protein using both 15N amide and 13C 
methyl CSPs. CSP results seem to be unambiguous in cases where a ligand binds at 
a defined binding site.   
In general, CSP analysis can be routinely applied to molecular weight systems 
up to 40-50 kDa.  However, in some cases the resonance assignments for large 
molecular weight systems (> 60 kDa) cannot be obtained due to their poor NMR 




isotope labeling and/or paramagnetic NMR methods can be quite useful.3,4 Sidechain 
methyl CSPs are comparatively more sensitive than the amide groups as long 
sidechain containing methyl groups extend out into the binding pocket.1 Hajduk and 
coworkers have demonstrated that 13C methyl CSPs can also be used on large 
molecular weight protein targets to screen a collection of compounds.7 Spectra of 
such proteins also have minimal overlap and therefore the interpretation of CSP data 
becomes easier.8 Using both the amide and/or sidechain methyl CSPs, it may be 
possible to classify the compounds in groups that bind to the same binding site on 
the protein target if they show CSPs for the same resonance, even if the assignment 
for those resonances is not available. This type of information may prove useful at 
early stages of the drug discovery. Based on the CSP results obtained for different 
molecular systems investigated in this thesis, it would be recommended, wherever 
possible, to observe both the amide and sidechain methyl CSPs to give a better 
coverage of the ligand binding site (Chapter 4). It should be kept in the mind that the 
structural information obtained by the CSP approach is of low resolution and does 
not contain sufficient detail to calculate precisely the orientation of a ligand in the 
binding site. To obtain the level of detail that includes the precise orientation of a 
ligand in the binding site, other structural restraints such as intermolecular NOEs 
should be used.  
 
Paramagnetic NMR to Investigate Protein-Ligand Interactions 
 Paramagnetic NMR is a widely used technique to study protein-protein 
interactions.3,4  As described earlier for the Rit1 work, the CSP analysis resulted in 
two binding sites for the compound and additional restraints were necessary to define 




by docking calculations proposed a novel mechanism by which the compound 
inhibits GDP-GTP exchange of Rit1. The docking generated model structures of Rit1 
bound to an inhibitor show that the Rit1-ligand complex is relatively dynamic. The 
ligand occupies two binding sites on the protein surface. In one of the binding sites, 
the ligand sterically blocks the GDP by binding over the top of the nucleotide binding 
site of the protein. This explains that by physically trapping the GDP, the ligand 
stabilizes the GDP bound form of the protein and nucleotide exchange is inhibited. 
Using the PRE based NMR method, we were able to understand the mechanism of 
inhibition of nucleotide exchange caused by the compound. This new binding site 
may point towards a new approach to inhibit this pharmaceutically important, yet 
challenging, class of targets. 
The Rit1 PRE-work demonstrates how NMR-based techniques can provide 
structural information even on dynamic protein-ligand complexes when other 
biophysical approaches to obtain binding site information are unsuccessful or 
ambiguous. The main advantage of the PRE based approach over using NOEs is 
that isotope labeled protein is not required. Here, a PRE approach was chosen over 
conventional NOEs as sidechain assignments for Rit1 were not readily available due 
to the marginal quality of the NMR spectra. NOE based studies require isotope 
labeled protein in large quantities and complete protein backbone and sidechain 
resonance assignments are necessary. Obtaining the required assignments can be 
challenging. For PRE-based work, only the ligand assignments are required and 
these are straightforward to obtain.   
The Rit1-PRE work shows a small molecule exchanging between multiple 
binding poses. It is conceivable that a ligand with a weak affinity towards a protein 




distinct multiple binding poses of small molecule ligands in binding sites of T4 
lysozyme, neutrophil elastase, estrogen receptor inhibitors, FKBP inhibitors, biotin -
streptavidin and cytochrome P450cam.9-15 Constantine et al have observed multiple 
binding modes of fragment-like kinase inhibitors using computational modeling and 
NMR studies.16 As a follow-up study to the Rit1 PRE work, it would be interesting to 
use paramagnetic pseudo-contact shifts to determine the same protein-ligand co-
structure. PCS provide long-range distance restraints (in the range of 10-40 Å) as 
well as relative orientations on the basis of the anisotropy of the magnetic 
susceptibility of paramagnetic metals. It would be interesting to see if the inclusion of 
pseudocontact shift datasets into docking calculations could also confirm the 
dynamic behavior of the Rit1-inhibitor complex. This should be readily possible as the 
application of pseudocontact shifts (PCS) in solving 3D atomic resolution structures 
of protein-small molecule complexes has been recently demonstrated by John et al 
and Guan et al.17,18 It would be interesting to combine the PCS data with molecular 
dynamic simulations to study dynamic protein-ligand complexes. This may help to 
differentiate the relative populations of the compound within the multiple binding 
poses. An extension of the Rit1 PRE-work can be applied to kinases, which are an 
important class of drug targets against oncology. There is an urgent need for 
selective kinase inhibitors that bind proximal to the ATP-binding site. The ATP site is 
highly conserved among protein kinases. The compounds that bind proximal to the 
ATP site might offer better selectivity. Here, spin labeled ATP can be used for the 
detection of compounds that bind outside the ATP site. A similar approach was 
shown by Janke et al.19 Methods like these can be broadly applied to screen for non-
ATP site binders. Overall, paramagnetic NMR methods present an alternative to 




Sparse NOE Data Leads to High Resolution Protein-Ligand Co-
structures 
The availability of protein-ligand co-structures allows the identification of 
essential interactions made by small molecule with the amino acid residues within the 
binding site of the target protein.1 These key interactions can then be improved upon 
by medicinal chemistry approaches leading towards compounds with better 
specificity, potency and ligand efficiency. The Hsp90 work in Chapter 4 demonstrates 
an NMR method that is based on the production of a protein target that is selectively 
isotopically labeled with the methyl groups of isoleucine, leucine and valine residues 
and acquisition of a limited number of intermolecular NOE restraints.13 In this method 
standard NOESY experiments were used to obtain a set of intermolecular NOEs 
between the protein-ligand complex. The NOE-based 3D co-structures of the Hsp90-
fragment complex obtained using our method revealed interesting difference when 
compared with the available crystal structures for the identical ligand with Hsp90 in 
the PDB. The crystal structures show that two or more low energy conformations of 
the ligand are present in the complex.  In contrast, the NMR data indicate that in 
solution, there is one predominant ligand conformation. Importantly, despite the 
moderate number of intermolecular restraints, the NMR defines precisely the same 
binding site as the crystal structure and the critical intermolecular hydrogen bonds.2  
The method developed in Chapter 4 shows that a universal selective labeling 
scheme can be used to rapidly identify sufficient numbers of restraints for a small-
molecule ligand weakly bound to protein. This chapter demonstrates how a 
combination of selective methyl group labeling, standard NMR experiments and 
computational docking can be used to rapidly determine the 3D structure of a small 




weight systems are restrained due to fast signal decay and severe peak overlap. The 
method utilizes selective labeling and advanced NMR experiments that have allowed 
structural studies on proteins up to ~100 kDa.20 Various groups have also undertaken 
steps towards achieving the resonance assignments using paramagnetic NMR. 
These were demonstrated to work on various molecular systems previously 
considered difficult for the resonance assignment. Implementation of selective methyl 
group labeling in conjunction with automated resonance assignment assisted by 
paramagnetic NMR should enable structure determination of complexes on 
reasonably large proteins.17,21-25 As the method requires only a sparse set of 
intermolecular NOEs, it presents an alternative to time consuming traditional NMR 
approaches that involve uniform isotope labeling and a large number of structural 
restraints. However, the present method depends on the availability of the structure 
of the target or a good homology model. The method also relies on the production of 
selectively labeled, deuterated protein, which can be performed only in E. coli. 
Another obvious limitation is the requirement for methyl groups at the ligand binding 
site. However, it is also possible to selectively label all methyl containing residues 
(Ala, Met, Thr, Ile, Leu and Val) providing even more complete coverage of protein 
structures and ligand binding sites.26 I think that the method combined with above 
adaptations could be even more powerful and prove valuable for the early stages of 
FBDD by reliably providing 3D structure information on weakly binding fragment-
protein complexes. 
 In my current position at ZoBio BV, a company that provides tools for 
FBDD in the pharmaceutical industry, the NMR methods described in Chapter 2, 3 
and 4 are being implemented routinely in FBDD projects. The results have led to a 




have sufficient speed and precision to support fragment hit to lead medicinal 
chemistry efforts. 
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NMR methods are used for a variety of applications in a drug discovery 
process to guide hit to lead development and ultimately to generate potential drug 
candidates. The availability of 3D structural information on protein-ligand complexes 
is crucial during various stages of drug development. NMR based methods are 
sensitive toward weak protein-ligand interactions and are applicable where X-ray 
crystallography is least effective i.e. for weakly bound ligands. However, traditional 
NMR approaches that involve uniform isotopic labeling are labor intensive and limited 
by the size of protein targets (e.g., < 30-40 kDa). Therefore, these have not been 
widely adopted in drug discovery. The main focus of the work described in this thesis 
was to develop and implement efficient NMR methods that are capable of providing 
3D structural information on protein-ligand complexes in the early stages of the drug 
discovery projects. The work presented in this thesis covers a wide range of classical 
and newly developed NMR techniques applied to diverse molecular systems.  
Chapter 1 provides general introduction to the drug discovery process, in 
particular, to the fragment-based drug discovery. The chapter also describes NMR 
methods that are often used for screening purposes and to obtain 3D structural 
information on protein target-small molecule complexes.    
In Chapter 2, a fragment based- small molecule discovery approach was 
sought to discover inhibitors that disrupt the DNA binding capability of TEL, a target 
for oncology. TEL is a DNA binding protein involved in transcriptional regulation of 
many cellular proteins that are involved in the regulation of angiogenesis. TEL is 
considered to be a therapeutic target for pathological angiogenesis in tumor cells. 
Chapter 2 describes the techniques and approaches that were undertaken to 
discover small molecule ligands that specifically bind the DNA binding ETS-domain 




applied. To demonstrate the DNA binding capability of TELETS, different array of 
techniques were used. Biochemical and structural analysis were performed using 
protein observed NMR, Surface Plasmon Resonance (SPR) and gel-shift assay to 
characterize DNA binding activity of TEL. The availability of the resonance 
assignments allowed determining the binding site of DNA and fragments hits. Based 
on the chemical shift perturbation analysis and CSP mapping, it was clearly observed 
that the binding site for the DNA and three fragments was common on the protein 
surface. To investigate whether these fragments were capable of disrupting the 
TELETS-DNA complex, a gel retardation assay was performed. The assay results 
indicated that the TELETS-DNA complex could be disrupted in the presence of high 
(millimolar) concentrations of 2 fragments. Clearly, the affinity for these fragments 
appears to be very low and the specificity, in relation to the other ETS-containing 
proteins remains to be tested. However, these fragments represent valuable starting 
points for further stages of drug discovery on TELETS. This work demonstrates how 
the application of NMR screening can be efficiently used to discover fragment hits 
and protein-observed NMR studies can be used to obtain low resolution structural 
information on protein-ligand complexes.  
In Chapter 3, a fragment based- small molecule discovery approach was 
initiated to discover small molecule inhibitors for Rit1 GTPase, a target for 
rheumatoid arthritis. Cellular studies carried out by Galapagos BV showed that 
inactivation of Rit1 reduced the levels of matrix metalloproteinases (MMPs) in bone 
cartilage tissue and that increased expression of Rit1 caused MMP levels to 
increase. MMPs are responsible for degradation of cartilage tissue and hence cause 
RA. Therefore, development of small molecule inhibitors that could inactivate Rit1 is 




fragment based screening, crystallization, analoging (compounds with similar 
chemical structures), hit development and a structural study on the most potent 
compound. A diverse range of techniques and methods was employed. Fragment 
hits were discovered using TINS NMR. The fragment hits were further tested in an in 
vitro biochemical assay. These hits and analog compounds were able to inhibit the 
GDP-GTP nucleotide exchange. In other words, compounds were able to stabilize 
the GDP bound inactive state of Rit1. Despite their functional inhibition, the 
mechanism of action of compounds remained elusive. High resolution 3D structures 
of the protein-compound would give a direct insight into the mechanism. The 
crystallography efforts yielded a high resolution 3D structure of the Rit1 bound to 
GDP nucleotide but efforts to obtain 3D structures on protein-ligand complexes 
failed. Substantial efforts to crystallize the complex were not successful due to the 
low solvent content of the protein crystals and cracking of protein crystals in the 
presence of the most potent compound. To address this issue, a solution based NMR 
approach was necessary and a paramagnetic NMR based approach was sought, 
whereby a spin label was introduced on GDP to obtain GDP-spin label. The 
paramagnetic NMR approach was combined with CSP analysis to obtain low 
resolution information on the binding site of ligands. Paramagnetic studies using the 
GDP-spin label followed by docking calculations proposed a novel mechanism by 
which the compound inhibits GDP-GTP exchange of Rit1. In one of the binding sites, 
the ligand sterically blocks the GDP nucleotide by binding over the top of the 
nucleotide binding site of the protein. This explains that by physically trapping the 
GDP nucleotide, the ligand stabilizes the GDP bound form of the protein and the 
nucleotide exchange with GTP is inhibited. This work shows how NMR-based 




obtain binding site information are unsuccessful. Here, using the PRE based NMR 
method, we were able to understand the mechanism exhibited by the compounds to 
achieve the inhibition of nucleotide exchange. PRE based methods present an 
alternative to obtain binding site information when other high resolution techniques 
fail. In principle, GDP-SL can be used to investigate any other GTPase.   
In Chapter 4, a solution NMR method was developed to obtain 3D structures 
of protein-small molecule complexes in rapid and efficient manner. The method was 
developed using the Hsp90-fragment complex as a model system. Hsp90 interacts 
with a large number of client proteins and it is thought that ATP hydrolysis is the main 
driver for these interactions and for this reason many drug discovery approaches 
have focused on targeting the ATP binding pocket in the N-terminal domain of 
Hsp90. The method described in Chapter 4 makes use of a small molecule fragment 
that binds in the ATP binding pocket of the N-terminal Hsp90 discovered by TINS 
NMR screening. The main goal was to use this protein-ligand system to develop an 
efficient way to obtain 3D structural information on protein bound to a ligand. In 
Chapter 4, an NMR method that is based on the production of a protein target that is 
selectively isotopically labeled with the methyl groups of isoleucine, leucine and 
valine residues is described. In this method standard NOESY experiments were used 
to obtain a set of intermolecular NOEs between the protein-ligand complex. The 
intermolecular NOEs were used as distance restraints to obtain 3D co-structures by 
molecular docking. The crystal structures were available for the identical ligand with 
Hsp90 in the PDB. The crystal structures show that two or more low energy 
conformations of the ligand are present in the complex.  In contrast, the NMR data 
indicate that in solution, there is one predominant ligand conformation. Importantly, 




the same binding site as the crystal structure and the critical intermolecular hydrogen 
bonds, suggesting that in addition to being fast, the method is robust. The method 
shows that a universal selective labeling scheme can be used to rapidly identify 
sufficient numbers of restraints for a small-molecule ligand weakly bound to protein. 
This chapter demonstrates how a combination of selective methyl group labeling, 
standard NMR experiments and computational docking can be used to rapidly 
determine the 3D structure of a small molecule bound “weakly” to a protein target. 
The approach requires only a sparse set of intermolecular NOEs and is an alternative 
to time consuming traditional NMR approaches that involve uniform isotope labeling. 
This method is also amenable to large molecular weight targets.
Chapter 5 presents the general discussion of the work and provides future 























             
 
   
 
  




In de ontwikkeling van geneesmiddelen worden NMR-methoden gebruikt voor tal van 
toepassingen in het proces van hit-to-lead en de uiteindelijke ontwikkeling van 
potentiële medicijnkandidaten. De beschikbaarheid van 3D structuurinformatie in 
eiwit-ligand complexen is cruciaal tijdens de verschillende fasen van 
medicijnontwikkeling. Methoden die op NMR zijn gebaseerd, zijn gevoelig voor 
zwakke eiwit-ligand interacties, in het gebied waar Röntgenkristallografie het minst 
effectief is. Helaas zijn traditionele NMR-benaderingen, die uniforme isotoopverrijking 
vereisen, arbeidsintensief en beperkt tot kleinere eiwitten (< 30-40 kDa) en daarom 
worden deze methoden niet op grote schaal gebruikt in medicijnontwikkeling. Het 
belangrijkste doel van het in dit proefschrift beschreven werk was daarom het 
ontwikkelen en implementeren van efficiënte NMR-technieken die 3D 
structuurinformatie van eiwit-ligand complexen kunnen opleveren voor het gebruik in 
de vroege stadia van medicijnontwikkeling. Het werk bestrijkt een groot gebied van 
klassieke en nieuw-ontwikkelde NMR-technieken, toegepast op diverse moleculaire 
systemen. 
 
Hoofdstuk 1 geeft een algemene introductie in het proces van medicijnontwikkeling, 
in het bijzonder de fragment based drug discovery. Dit hoofdstuk beschrijft ook de 
NMR-methoden die vaak worden gebruikt voor screening doeleinden en om 3D 
structuurinformatie van complexen tussen target eiwitten en kleine moleculen te 
verkrijgen. 
 
In hoofdstuk 2 wordt een fragment based small molecule discovery benadering 
getoetst om remmers te vinden die het bindend vermogen van TEL, een target-eiwit 




de transcriptieregulatie van veel cellulaire eiwitten die een rol spelen bij angiogenese. 
TEL wordt beschouwd als een therapeutisch target voor pathologische angiogenese 
in tumoren. In hoofdstuk 2 worden de technieken en benaderingen beschreven die 
zijn toegepast om kleine moleculen te vinden die specifiek associëren met het DNA-
bindende ETS-domein van TEL. Een TINS NMR fragment screen werd uitgevoerd 
om de primaire hit-materie (alle bindende moleculen) te vinden. Om het resterende 
DNA-bindende vermogen van TELETS te bepalen zijn verschillende technieken 
gebruikt. Biochemische analyse en structuuranalyse werden uitgevoerd met behulp 
van NMR-spectroscopie aan het eiwit en Surface Plasmon Resonance (SPR) en een 
gel-shift assay werden gebruikt om de DNA-binding van TEL te beschrijven. De 
reeds beschikbare resonantietoekenningen maakten het mogelijk om de 
bindingsplaats van zowel het DNA als de hit-fragmenten op het eiwitoppervlak vast te 
stellen. Met behulp van chemical shift perturbation analyse kon duidelijk worden 
vastgesteld dat de bindingsplaats voor het DNA overeenkwam met die van drie 
fragmenten. Om te onderzoeken of deze fragmenten het TELETS-DNA complex 
kunnen verstoren werd een gelretardatie-test uitgevoerd. De resultaten toonden aan 
dat het TELETS-DNA complex kon worden verstoord in de aanwezigheid van hoge 
(millimolair) concentraties van twee fragmenten. De affiniteit voor deze fragmenten is 
duidelijk erg laag en de specificiteit ten opzichte van andere ETS-bevattende eiwitten 
moet nog worden onderzocht. Toch vertegenwoordigen deze fragmenten 
waardevolle uitgangspunten voor medicijnontwikkeling met betrekking tot TELETS. Dit 
werk laat zien dat de toepassing van NMR screening op een efficiënte manier kan 
worden gebruikt om hit-fragmenten te vinden en dat NMR aan het eiwit kan worden 





In hoofdstuk 3 staat beschreven hoe een fragment based small molecule discovery 
benadering werd geïnitieerd om kleine-molecule remmers te vinden voor Rit1 
GTPase, een target voor reumatoïde artritis. Cellulaire studies, uitgevoerd door 
Galapagos BV, lieten zien dat het inactiveren van Rit1 leidde tot lagere 
hoeveelheden van matrix metalloproteinen (MMPs) in kraakbeen en dat toegenomen 
expressie van het gen voor Rit1 die hoeveelheden deed stijgen. MMPs zijn 
verantwoordelijk voor vermindering van kraakbeenweefsel en veroorzaken dus RA. 
Daarom is de ontwikkeling van kleine-molecule remmers die Rit1 kunnen inactiveren 
belangrijk voor een mogelijke behandeling van RA. Hoofdstuk 3 beschrijft de 
verkregen resultaten van fragment based screening, kristallisatie, analoging 
(evaluatie van moleculen met vergelijkbare structuur), hit development en een 
structuuronderzoek van de meest potente verbinding. Een reeks van diverse 
technieken en methoden werd toegepast. Hit-fragmenten werden gevonden met 
behulp van TINS NMR. Deze fragmenten werden nader getest in een in vitro 
biochemische test. De hits en analoge verbindingen konden de GDP/GTP 
nucleotide-uitwisseling verhinderen. Met andere woorden, de verbindingen waren in 
staat om de inactieve, GDP-gebonden toestand van Rit1 te stabiliseren. Het 
mechanisme van deze remmende werking was onduidelijk. Hoge-resolutie 3D 
structuren van het eiwit-molecule complex zouden inzicht in dit mechanisme kunnen 
geven. Kristallisatie leverde weliswaar een hoge-resolutie 3D structuur van Rit1 
gebonden aan GDP nucleotiden op, maar 3D structuren van eiwit-ligand complexen 
konden niet worden verkregen. Veel pogingen om het complex te kristalliseren 
bleven zonder succes, vanwege het lage gehalte aan oplosmiddel in de 
eiwitkristallen en omdat de eiwitkristallen braken in de aanwezigheid van de meest 




noodzakelijk. Er werd een paramagnetische NMR methode toegepast, waarbij een 
spin label op GDP werd aangebracht om een GDP-spin label te verkrijgen. De 
paramagnetische NMR-benadering werd gecombineerd met CSP analyse om lage-
resolutie informatie over de bindingsplaats van de liganden te verkrijgen. Op grond 
van de paramagnetische studies met de GDP-spin label, gevolgd door docking 
berekeningen, is een nieuw mechanisme voorgesteld voor het afremmen van de 
GDP/GTP-uitwisseling van Rit1 door de verbinding. Het ligand blokkeert de GDP-
nucleotide aan de ‘bovenkant’ van de nucleotide-bindingsplaats op het eiwit. Door 
fysiek afschermen van de nucleotide door het ligand wordt de GDP-gebonden 
toestand van het eiwit gestabiliseerd en de nucleotide-uitwisseling met GTP 
verhinderd. Dit werk laat zien hoe op NMR-gebaseerde methoden, in dit geval 
gebruik makend van paramagnetische relaxatie, structuurinformatie kunnen geven in 
gevallen waar andere biofysische technieken zonder resultaat blijven.  In principe 
kan het GDP-spin label worden gebruikt om elke andere GTPase te bestuderen. 
 
In hoofdstuk 4 staat beschreven hoe een andere methode voor vloeistof-NMR is 
ontwikkeld om op een snelle en efficiënte manier 3D structuurinformatie van 
complexen tussen eiwitten en kleine moleculen te verkrijgen. Bij de ontwikkeling van 
deze methode werd gebruik gemaakt van een Hsp90-fragment complex als 
modelsysteem. Hsp90 gaat interacties aan met een groot aantal andere eiwitten. 
Verondersteld wordt dat de hydrolyse van ATP de drijvende kracht is achter deze 
wisselwerkingen. Dit is de reden waarom veel medicijnontwikkeling gericht is op het 
ontwikkelen van moleculen die binden in de ATP-bindingsplek in het N-terminale 
domein van Hsp90. De methode maakt gebruik van een fragment dat bindt in de 




belangrijkste doel was om met behulp van dit eiwit/ligand-systeem een efficiënte 
manier te ontwikkelen om 3D structuurinformatie van een aan een ligand gebonden 
eiwit te verkrijgen. De methode is gebaseerd op het gebruik van eiwit dat selectief is 
verrijkt met isotopen in de methylgroepen van isoleucine, leucine en valine residuen. 
Bij deze methode worden standaard NOESY experimenten gebruikt om een reeks 
intermoleculaire NOEs in het eiwit-ligand complex te verkrijgen. Deze NOEs werden 
gebruikt om 3D co-structuren te verkrijgen door moleculaire docking. De 
kristalstructuren waren voor hetzelfde ligand gebonden aan Hsp90 waren reeds 
beschikbaar in de PDB. Deze structuren laten zien dat er twee of meer lage-energie 
conformaties van het ligand aanwezig zijn in het complex. In tegenspraak hiermee 
tonen de NMR data aan dat er in oplossing slechts één overheersende 
ligandconformatie aanwezig is. Het is een belangrijke vinding dat, ondanks het 
bescheiden aantal intermoleculaire contacten, de NMR-methode precies dezelfde 
bindingsplaats en kritische intermoleculaire waterstofbruggen definieert als de 
kristalstructuur laat zien. Dit suggereert dat de methode niet alleen snel maar ook 
robuust is. De methode laat zien dat een universele selectieve verrijkingsstrategie 
kan worden gebruikt om snel een voldoende aantal contacten te identificeren voor 
een klein molecule dat zwak gebonden is aan een eiwit. Het vormt ook een 
alternatief voor tijdrovende traditionele NMR benaderingen die uniforme 
isotoopverrijking met zich mee brengen. De methode is ook toe te passen op eiwitten 
met hoge moleculegewichten. 
 
In hoofdstuk 5 wordt een algemene discussie van het werk gegeven en er worden 
toekomstperspectieven besproken voor de ontwikkelde en toegepaste NMR-
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